{"content":"<li class=\"n-box-item date-title\" data-end=\"1549429199\" data-start=\"1549342800\" data-txt=\"Monday, December 23, 2019\">Tuesday, February  5, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3429972\" data-ts=\"1549411006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429972-intelsat-gets-late-lift-kerrisdale-teases-squeeze-on-long-position\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat gets late lift as Kerrisdale teases &#39;squeeze&#39; on long position</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) is on the move after hours on heavy NYSE volume, <font color=\"green\">up 2.8%</font>, in likely anticipation of some new positivity from a short seller who got in the company's corner last summer.</li>    <li>Kerrisdale Capital went <a href=\"https://seekingalpha.com/article/4184057-intelsat-s-ses-s-moon\" target=\"_blank\">long Intelsat</a> last June, saying the company and peer SES (<a href='https://seekingalpha.com/symbol/SGBAF' title='Ses Global SA'>OTCPK:SGBAF</a>) stood to benefit \"massively\" if the FCC allowed their plan to monetize C-band spectrum to go forward.</li>    <li>A <a href=\"https://twitter.com/KerrisdaleCap/status/1092892054731046912\" target=\"_blank\">Kerrisdale tweet</a> after the close doesn't name the company, but says \"We're releasing an update on our favorite long and largest position tomorrow. Conference call at 11 a.m.\"</li>    <li>It continues: \"Thesis playing out and 2019 shaping up to be catalyst-rich, yet short interest hitting 12-month highs. Squeeze?\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429972\" data-linked=\"Intelsat gets late lift as Kerrisdale teases &#39;squeeze&#39; on long position\" data-tweet=\"$I $SGBAF - Intelsat gets late lift as Kerrisdale teases &#39;squeeze&#39; on long position https://seekingalpha.com/news/3429972-intelsat-gets-late-lift-kerrisdale-teases-squeeze-on-long-position?source=tweet\" data-url=\"https://seekingalpha.com/news/3429972-intelsat-gets-late-lift-kerrisdale-teases-squeeze-on-long-position\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429967\" data-ts=\"1549408569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429967-activision-take-two-lower-after-ea-cuts-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Activision, Take-Two lower after EA cuts guidance</a></h4><ul>   <li>With Electronic Arts (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>) suffering postmarket (<font color=\"red\">down 17%</font>) after its <a href=\"https://seekingalpha.com/news/3429897-electronic-arts-minus-10_6-percent-q3-miss-trimmed-guidance\" target=\"_blank\">Q3 miss</a>, big videogame publishers are feeling the pain of EA's guidance cuts.</li>    <li>Activision Blizzard (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc'>ATVI</a>) is <font color=\"red\">down 3.5%</font> after hours, while Take-Two (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) is <font color=\"red\">1.2% lower</font>.</li>    <li>EA guided well below expectations for current-quarter net bookings and cut its adjusted revenue forecast by 6% and its adjusted profit expectations by 16%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429967\" data-linked=\"Activision, Take-Two lower after EA cuts guidance\" data-tweet=\"$EA $EA $ATVI - Activision, Take-Two lower after EA cuts guidance https://seekingalpha.com/news/3429967-activision-take-two-lower-after-ea-cuts-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3429967-activision-take-two-lower-after-ea-cuts-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429966\" data-ts=\"1549408253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOYA\" target=\"_blank\">VOYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429966-voyaplus-1_5-q4-normalized-eps-beats-18-cents\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Voya +1.5% as Q4 normalized EPS beats by 18 cents</a></h4><ul><li>Voya Financial (NYSE:<a href='https://seekingalpha.com/symbol/VOYA' title='Voya Financial, Inc.'>VOYA</a>)<font color=\"green\"> gains 1.5%</font> in after-hours trading after Q4 normalized EPS of $1.40 beat the average analyst estimate of $1.22.</li><li>Comes in at the high end of $1.30-$1.40 EPS target set for Q2 2019-end.</li><li>Organic growth:</li></ul><ol><li>Q4 retirement adjusted operating earnings of $183M, rose 14% Y/Y, driven by higher investment income and fee-based margins.</li><li>Q4 investment management adjusted operating earnings of $44M and generated $694M of institutional net inflows.</li><li>Q4 employee benefits adjusted operating earnings of $43M rose 39% Y/Y driven by an improved loss ratio for stop loss.</li></ol><ul><li>Total company assets under management and administration of $467B as of Dec. 31, 2018.</li><li>Common book value, excluding AOCI, of $48.26 per share at Dec. 31, 2018 vs. $42.31 at Dec. 31, 2017.</li><li><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.voya.com&amp;esheet=51936229&amp;newsitemid=20190205005972&amp;lan=en-US&amp;anchor=investors.voya.com&amp;index=2&amp;md5=910091ea597e32c3fbe2b53a99680743\" target=\"_blank\">Conference call</a> on Feb. 6 at 10:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429863-voya-financial-beats-0_10\" target=\"_blank\">Voya Financial beats by $0.10</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429966\" data-linked=\"Voya +1.5% as Q4 normalized EPS beats by 18 cents\" data-tweet=\"$VOYA - Voya +1.5% as Q4 normalized EPS beats by 18 cents https://seekingalpha.com/news/3429966-voyaplus-1_5-q4-normalized-eps-beats-18-cents?source=tweet\" data-url=\"https://seekingalpha.com/news/3429966-voyaplus-1_5-q4-normalized-eps-beats-18-cents\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429965\" data-ts=\"1549408162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APPS\" target=\"_blank\">APPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429965-digital-turbineplus-4_6-after-strongest-quarter-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Turbine +4.6% after its &#39;strongest&#39; quarter, upside guidance</a></h4><ul>   <li>Digital Turbine (NASDAQ:<a href='https://seekingalpha.com/symbol/APPS' title='Digital Turbine, Inc.'>APPS</a>) is <font color=\"green\">up 4.6%</font> postmarket after its fiscal Q3 report and fiscal-year guidance topped expectations.</li>    <li>The quarter was \"easily the strongest in the company's history across a wide range of operational and financial metrics,\" says CEO Bill Stone.</li>    <li>Revenue grew by a third and the company swung to a gain of $3M on a non-GAAP basis, from a year-ago loss of $0.8M.</li>    <li>EBITDA hit $3.8M vs. near-zero a year ago.</li>    <li>The company's surpassed 230M total devices with Ignite installed after 28M installs in the December quarter.</li>    <li>U.S. revenue per device rose 41% and global RPD rose 7%.</li>    <li>Cash from operations was $2.7M, and free cash flow was $2M.</li>    <li>It's guiding to full-year revenue of $102.5M-$103.5M (above consensus for $101.5M) and EBITDA of $7.3M-$7.8M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429872-digital-turbine-beats-0_04-beats-revenue\" target=\"_blank\">Digital Turbine beats by $0.04, beats on revenue</a> (Feb. 05 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17402767-digital-turbine-reports-fiscal-2019-third-quarter-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429965\" data-linked=\"Digital Turbine +4.6% after its &#39;strongest&#39; quarter, upside guidance\" data-tweet=\"$APPS - Digital Turbine +4.6% after its &#39;strongest&#39; quarter, upside guidance https://seekingalpha.com/news/3429965-digital-turbineplus-4_6-after-strongest-quarter-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3429965-digital-turbineplus-4_6-after-strongest-quarter-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429961\" data-ts=\"1549407437\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAVE\" target=\"_blank\">SAVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429961-spirit-airlinesminus-2-after-q1-unit-revenue-forecast-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spirit Airlines -2% after Q1 unit revenue forecast disappoints</a></h4><ul><li>Spirit Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a>) <font color=\"red\">drops 2.2%</font> in AH trading after the company says it expects <a href=\"https://seekingalpha.com/pr/17402722-spirit-airlines-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Q1</a> unit revenue to decelerate to a +5% pace from the 11.4% mark just recorded in Q4.</li><li>The airline company says it's benefiting from improved yield management processes, non-ticket revenue initiatives, strategic network re-orientation and a strong operating environment.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429838-spirit-airlines-eps-line-beats-revenue\" target=\"_blank\">Spirit Airlines EPS in-line, beats on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429961\" data-linked=\"Spirit Airlines -2% after Q1 unit revenue forecast disappoints\" data-tweet=\"$SAVE - Spirit Airlines -2% after Q1 unit revenue forecast disappoints https://seekingalpha.com/news/3429961-spirit-airlinesminus-2-after-q1-unit-revenue-forecast-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3429961-spirit-airlinesminus-2-after-q1-unit-revenue-forecast-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429957\" data-ts=\"1549407120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNW\" target=\"_blank\">GNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429957-genworthminus-5_4-after-posting-q4-adjusted-operating-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genworth -5.4% after posting Q4 adjusted operating loss</a></h4><ul><li>Genworth (NYSE:<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a>)<font color=\"red\"> falls 5.4%</font> in after-hours trading as the insurer records <a href=\"https://seekingalpha.com/pr/17402879-genworth-financial-announces-fourth-quarter-2018-results\" target=\"_blank\">adjusted operating loss</a> of 58 cents per share in Q4 vs. adjusted operating income of 65 cents in the year- ago quarter.</li><li>Sees reaching an agreement with Canada soon on its pending acquisition by Oceanwide Holdings.</li><li>The transaction still needs approval from authorities in China and by the U.S. Financial Industry Regulatory Authority.</li><li>Records Q4 adjusted operating loss of $291M vs. income of $145M in Q3 and income of $326M in Q4 2017; by segment:</li></ul><ol><li>U.S. Mortgage insurance: adjusted operating income of $124M vs. $118M in Q3 and $74M in Q4 2017;</li><li>Canada Mortgage insurance: adjusted operating income of $48M vs. $44M in Q3 and $43M in Q4 2017;</li><li>Australia Mortgage insurance: adjusted operating income of $18M vs. $17M in Q3 and loss of $125M in Q4 2017.</li><li>U.S. life insurance: adjusted operating loss of $425M vs. loss of $3M in Q3 and loss of $69M in Q4 2017.</li></ol><ul><li>Book value per share excluding accumulated other comprehensive income of $20.78 at Dec. 31, 2018 compares with $26.88 at Dec. 31, 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429951-genworth-financial-misses-0_84-misses-revenue\" target=\"_blank\">Genworth Financial misses by $0.84, misses on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429957\" data-linked=\"Genworth -5.4% after posting Q4 adjusted operating loss\" data-tweet=\"$GNW - Genworth -5.4% after posting Q4 adjusted operating loss https://seekingalpha.com/news/3429957-genworthminus-5_4-after-posting-q4-adjusted-operating-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3429957-genworthminus-5_4-after-posting-q4-adjusted-operating-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>91&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429952\" data-ts=\"1549406193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARLO\" target=\"_blank\">ARLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429952-arlominus-22-after-market-slowdown-prompts-weak-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arlo -22% after market slowdown prompts weak guidance</a></h4><ul>   <li>Arlo (NYSE:<a href='https://seekingalpha.com/symbol/ARLO' title='Arlo Technologies'>ARLO</a>) has crumpled after hours, <font color=\"red\">down 22.3%</font> in heavy trading, after its Q4 beat contained highly disappointing guidance amid a significant market slowdown.</li>    <li>After a \"transformational year,\" the company \"saw the market growth slow significantly late in 2018 which led to channel inventory buildup and both of these factors will affect our growth expectations for 2019,\u201d says CEO Matthew McRae.</li>    <li>Based on carve-out financials, revenues ticked up 3.6% to $129.3M, and the company didn't lose as much as expected.</li>    <li>Gross margin (non-GAAP) declined to 9.9% from last year's 24.4%, however.</li>    <li>Paid subscribers grew 84.6% Y/Y, and cumulative registered user growth was 70.7%.</li>    <li>But for Q1 it's guiding to revenues of $48M-$52M, a distance below consensus for $126.5M, non-GAAP gross margin of 0% to 3.0%, and EPS of -$0.51 to -$0.55 (vs. expectations for -$0.24).</li>    <li>For the full year, it's guiding to revenue of $380M-$420M (well short of expected $606.5M), and a non-GAAP operating loss of $95M-$105M.</li>    <li><a href=\"https://seekingalpha.com/article/4238335-arlo-technologies-2018-q4-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3429840-arlo-technologies-beats-0_02-beats-revenue\" target=\"_blank\">Arlo Technologies beats by $0.02, beats on revenue</a> (Feb. 05 2019)</li>   <li><a href=\"https://seekingalpha.com/pr/17402688-arlo-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429952\" data-linked=\"Arlo -22% after market slowdown prompts weak guidance\" data-tweet=\"$ARLO - Arlo -22% after market slowdown prompts weak guidance https://seekingalpha.com/news/3429952-arlominus-22-after-market-slowdown-prompts-weak-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3429952-arlominus-22-after-market-slowdown-prompts-weak-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429948\" data-ts=\"1549406065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429948-snap-ea-vrtx-and-viav-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SNAP, EA, VRTX and VIAV among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color=\"green\">+18.4%</font>. <a href='https://seekingalpha.com/symbol/ZEN' title='Zendesk, Inc.'>ZEN</a> <font color=\"green\">+6.4%</font>. <a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a> <font color=\"green\">+6.1%</font>. <a href='https://seekingalpha.com/symbol/PAYC' title='Paycom Software, Inc.'>PAYC</a> <font color=\"green\">+5.9%</font>. <a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color=\"green\">+3.3%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/ARLO' title='Arlo Technologies'>ARLO</a> <font color=\"red\">-21.5%</font>. <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color=\"red\">-16.9%</font>. <a href='https://seekingalpha.com/symbol/TCS' title='The Container Store Group, Inc.'>TCS</a> <font color=\"red\">-16.4%</font>. <a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a> <font color=\"red\">-13.3%</font>. <a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> <font color=\"red\">-12.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429948\" data-linked=\"SNAP, EA, VRTX and VIAV among after hour movers\" data-tweet=\"$SNAP $SNAP $ZEN - SNAP, EA, VRTX and VIAV among after hour movers https://seekingalpha.com/news/3429948-snap-ea-vrtx-and-viav-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429948-snap-ea-vrtx-and-viav-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429943\" data-ts=\"1549405226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCLP\" target=\"_blank\">HCLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429943-hi-crush-partnersplus-1_5-after-q4-results-not-bad-expected\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hi-Crush Partners +1.5% after Q4 results not as bad as expected</a></h4><ul><li>Hi-Crush Partners (NYSE:<a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a>) <font color=\"green\">+1.5%</font> after-hours as it reports a slightly smaller than expected <a href=\"https://seekingalpha.com/news/3429881-hi-crush-partners-beats-0_01-beats-revenue\" target=\"_blank\">Q4 loss</a> and a 25% Y/Y revenue decline that nevertheless came in better than analyst expectations.</li><li>HCLP says Q4 frac sand sales volumes fell 28.7% Y/Y to 1.97M tons from 2.77M tons in the prior-year quarter, citing lower completion activity and competitive pressures from additional in-basin supply coming online.</li><li>Q4 average sales price was $58/ton vs. $64/ton in Q3, a result of the slowdown in demand for frac sand that emerged during Q3 2018 and continued throughout Q4 due to decreased well completion activity, exacerbated by the start-up of new in-basin production capacity in the Permian.</li><li>HCLP says Q4 contribution margin fell 40% Q/Q to $14.35/ton from $23.92/ton but was in line with company guidance.</li><li>HCLP says it had 16 PropStream container crews in the Permian Basin and Marcellus/Utica plays, and 8 FB silo systems operating in the Permian at the end of Q4, and during the quarter it completed successful field testing for the new FB Atlas top-fill conveyor system with an existing E&amp;P customer in the Permian.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429943\" data-linked=\"Hi-Crush Partners +1.5% after Q4 results not as bad as expected\" data-tweet=\"$HCLP $HCR - Hi-Crush Partners +1.5% after Q4 results not as bad as expected https://seekingalpha.com/news/3429943-hi-crush-partnersplus-1_5-after-q4-results-not-bad-expected?source=tweet\" data-url=\"https://seekingalpha.com/news/3429943-hi-crush-partnersplus-1_5-after-q4-results-not-bad-expected\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429931\" data-ts=\"1549404343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIAV\" target=\"_blank\">VIAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429931-viaviplus-5_3-strong-revenues-lead-to-q2-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viavi +5.3% as strong revenues lead to Q2 beat</a></h4><ul>   <li>Viavi Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/VIAV' title='Viavi Solutions Inc.'>VIAV</a>) is <font color=\"green\">up 5.3%</font> postmarket after revenues jumped nearly 50% and topped consensus and the company jumped to a GAAP profit vs. a break-even quarter a year ago.</li>    <li>Net income/share rose to $0.07 from last quarter's -$0.07 and $0.00 a year ago.</li>    <li>Gross margin was near flat at 58% vs. a year-ago 58.1% (and up from last quarter's 56%).</li>    <li>Operating margin however jumped 730 basis points to 10.7%, and operating income rose 377% to $32.9M.</li>    <li>Revenue by segment: Network Enablement, $195.5M (up 60.2%); Service Enablement, $28.2M (down 19.9%); Optical Security and Performance Products, $83.2M (up 72.6%).</li>    <li>As of Dec. 29, it had $502.7M in cash and investments; for the quarter it generated $41.5M in cash from operations.</li>    <li>It's guiding to Q3 revenues of $247M-$267M (vs. consensus for $256.6M) and EPS of $0.11-$0.13 (in line with consensus for $0.12).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429815-viavi-solutions-beats-0_06-beats-revenue\" target=\"_blank\">Viavi Solutions beats by $0.06, beats on revenue</a> (Feb. 05 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17402656-viavi-announces-second-quarter-fiscal-2019-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429931\" data-linked=\"Viavi +5.3% as strong revenues lead to Q2 beat\" data-tweet=\"$VIAV - Viavi +5.3% as strong revenues lead to Q2 beat https://seekingalpha.com/news/3429931-viaviplus-5_3-strong-revenues-lead-to-q2-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3429931-viaviplus-5_3-strong-revenues-lead-to-q2-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429928\" data-ts=\"1549404141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DATA\" target=\"_blank\">DATA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429928-tableauminus-4_7-despite-q4-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tableau -4.7% despite Q4 beats</a></h4><ul><li>Tableau Software (NYSE:<a href='https://seekingalpha.com/symbol/DATA' title='Tableau Software'>DATA</a>) shares <font color=\"red\">drop 4.7%</font> on a Q4 report that beat EPS and revenue estimates. On the earnings call, Tableau reaffirms its FY19 revenue guidance at $1.33B to $1.4B (consensus: $1.35B).</li><li>Revenue breakdown (ASC 605): License, $151.8M (consensus: $143.5M); Maintenance &amp; Services, $124M (consensus: $126.7M).</li><li>Billings totaled $370.1M compared to the $373.3M estimate.</li><li>Tableau added over 3,000 new customer accounts in the quarter and closed 634 sales greater than $100K, up 8% Y/Y.</li><li><a href=\"https://seekingalpha.com/pr/17402695-tableau-reports-q4-full-year-2018-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429814-tableau-software-beats-0_05-beats-revenue\" target=\"_blank\">Tableau Software beats by $0.05, beats on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429928\" data-linked=\"Tableau -4.7% despite Q4 beats\" data-tweet=\"$DATA - Tableau -4.7% despite Q4 beats https://seekingalpha.com/news/3429928-tableauminus-4_7-despite-q4-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3429928-tableauminus-4_7-despite-q4-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429910\" data-ts=\"1549403003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APC\" target=\"_blank\">APC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429910-anadarkominus-2-after-q4-earnings-miss-reaffirms-2019-capex-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anadarko -2% after Q4 earnings miss; reaffirms 2019 capex program</a></h4><ul><li>Anadarko Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/APC' title='Anadarko Petroleum Corporation'>APC</a>) <font color=\"red\">-2.2%</font> after-hours as <a href=\"https://seekingalpha.com/news/3429861-anadarko-petroleum-misses-0_23-beats-revenue\" target=\"_blank\">Q4 earnings</a> miss Wall Street expectations by a wide mark, even as revenues rose 14.3% Y/Y to $3.35B, as <a href=\"https://www.wsj.com/articles/anadarko-hit-by-rising-costs-lower-oil-prices-11549403681\" target=\"_blank\">prices fell and costs rose</a>.</li><li>APC says Q4 sales volumes for oil, natural gas and natural gas liquids averaged 701K boe/day, up 10% from 637K boe/day in the year-ago quarter, while FY 2018 sales volumes averaged 666K boe/day; for FY 2019, APC forecasts total sales volume of 260M-270M boe vs. 243M boe in 2018.</li><li>But while sales volumes rose, APC's average selling price during the quarter fell to $59.86/bbl from $56.32/bbl and total expenses jumped 19% to $3.08B as the company ramped up investments in West Texas' Delaware Basin and Colorado's DJ Basin; APC also reports $226M in income taxes for Q4, compared with a $1.11B tax benefit in the year-ago quarter.</li><li>APC says it organically added 284M boe of proved reserves before the effects of price revisions during 2018 to 1.47B boe (63% liquids, 37% natural gas), with 78% of its reserves categorized as proved developed.</li><li>While expecting continued market volatility \"for some time,\" APC maintains previously announced capital spending plans of $4.3B-$4.7B, which enables it to operate within anticipated discretionary cash flow at $50/bbl oil and remain committed to maximizing capital efficiency and enhancing returns on a multi-year basis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429910\" data-linked=\"Anadarko -2% after Q4 earnings miss; reaffirms 2019 capex program\" data-tweet=\"$APC - Anadarko -2% after Q4 earnings miss; reaffirms 2019 capex program https://seekingalpha.com/news/3429910-anadarkominus-2-after-q4-earnings-miss-reaffirms-2019-capex-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3429910-anadarkominus-2-after-q4-earnings-miss-reaffirms-2019-capex-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429898\" data-ts=\"1549402291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBOT\" target=\"_blank\">SBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429898-stellar-biotechnologies-misses-0_03-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stellar Biotechnologies misses by $0.03, misses on revenue</a></h4><ul><li>Stellar Biotechnologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SBOT' title='Stellar Biotechnologies Inc.'>SBOT</a>): Q1 GAAP EPS of -$0.26 <span style=\"color:red\">misses by $0.03</span>.</li><li>Revenue of $0.05M (+150.0% Y/Y) <font color=\"red\">misses by $0.01M</font>.</li><li>Shares <font color=\"green\">+3.28%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17402787-stellar-biotechnologies-reports-first-quarter-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429898\" data-linked=\"Stellar Biotechnologies misses by $0.03, misses on revenue\" data-tweet=\"$SBOT $EDSA - Stellar Biotechnologies misses by $0.03, misses on revenue https://seekingalpha.com/news/3429898-stellar-biotechnologies-misses-0_03-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3429898-stellar-biotechnologies-misses-0_03-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429897\" data-ts=\"1549402286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429897-electronic-artsminus-10_6-after-q3-miss-trimmed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electronic Arts -10.6% after Q3 miss, trimmed guidance</a></h4><ul>   <li>Electronic Arts (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>) is <font color=\"red\">sliding 10.6%</font> after its Q3 report, where bookings and adjusted profit fell short of consensus and the company cut full-year guidance on both metrics.</li>    <li>While digital revenues of $1.2B were mostly in line, packaged goods and other revenues of $410M fell well short of consensus for $527.7M.</li>    <li>Gross profit rose to $876M, up 33% Y/Y. Gross margin came in at 77.4%.</li>    <li>Net revenue breakout: Product, $552M (up 0.9%); Service and other, $737M (up 20.2%).</li>    <li>\u201cQ3 was a difficult quarter for Electronic Arts and we did not perform to our expectations,\" says CEO Andrew Wilson. \"We are now applying the strengths of our company to sharpen our execution and focus on delivering great new games and long-term live services for our players.\"</li>    <li>For Q4 it's guiding to net bookings of about $1.17B, below consensus for $1.75B.</li>    <li>It expects 2019 adjusted revenue of about $4.875B, down from a previous forecast for $5.2B, and sees adjusted EPS coming in at $3.85 vs. a prior $4.57.</li>    <li><a href=\"http://ir.ea.com\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429810-electronic-arts-beats-0_30-misses-revenue\" target=\"_blank\">Electronic Arts beats by $0.30, misses on revenue</a> (Feb. 05 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17402667-electronic-arts-reports-q3-fy19-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429897\" data-linked=\"Electronic Arts -10.6% after Q3 miss, trimmed guidance\" data-tweet=\"$EA - Electronic Arts -10.6% after Q3 miss, trimmed guidance https://seekingalpha.com/news/3429897-electronic-artsminus-10_6-after-q3-miss-trimmed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3429897-electronic-artsminus-10_6-after-q3-miss-trimmed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429894\" data-ts=\"1549402213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429894-vertex-q4-non-gaap-earnings-up-113-shares-up-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex Q4 non-GAAP earnings up 113%; shares up 2% after hours</a></h4><ul><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) <a href=\"https://seekingalpha.com/pr/17402653-vertex-reports-full-year-fourth-quarter-2018-financial-results\" target=\"_blank\">Q4 results</a> ($M): Revenues: 870.1 (+33.5%); product revenues: 868.2 (+39.8%).</li><li>Key product sales: Kalydeco: 259 (+1.2%); Orkambi: 315 (-13.7%); Symdeko: 294.</li><li>Net income: 1,550.5 (+999%) - increase due to $1.5B income tax benefit. Non-GAAP net income: 336.9 (+113.4%).</li><li>EPS: $5.97 (+999%); non-GAAP EPS: 1.30 (+113.1%).</li><li><strong>2019 guidance</strong>: CF product revenues: $3.45B - 3.55B.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429801-vertex-pharmaceuticals-beats-0_24-beats-revenue\" target=\"_blank\">Vertex Pharmaceuticals beats by $0.24, beats on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429894\" data-linked=\"Vertex Q4 non-GAAP earnings up 113%; shares up 2% after hours\" data-tweet=\"$VRTX - Vertex Q4 non-GAAP earnings up 113%; shares up 2% after hours https://seekingalpha.com/news/3429894-vertex-q4-non-gaap-earnings-up-113-shares-up-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3429894-vertex-q4-non-gaap-earnings-up-113-shares-up-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429891\" data-ts=\"1549402160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429891-skyworks-solutionsplus-2-on-in-line-q1-2b-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyworks Solutions +2% on in-line Q1, $2B buyback</a></h4><ul><li>Skyworks Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>) <font color=\"green\">gains 2% </font>aftermarket on in-line Q1 results with downside Q2 guidance that has revenue from $800M to $820M (consensus: $851.49M) and EPS at $1.43 (consensus: $1.51).</li><li>Buyback: The board approves a new $2B <a href=\"https://seekingalpha.com/pr/17402734-skyworks-announces-new-2-billion-stock-repurchase-program\" target=\"_blank\">share repurchase</a> program, which entirely replaces the $1B program announced in early 2018 that had about $129M remaining. The new program expires January 30, 2021.</li><li>Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"http://investors.skyworksinc.com/investor-relations\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17402755-skyworks-reports-q1-fy19-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429854-skyworks-solutions-eps-revenue-line\" target=\"_blank\">Skyworks Solutions EPS and revenue in-line</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429891\" data-linked=\"Skyworks Solutions +2% on in-line Q1, $2B buyback\" data-tweet=\"$SWKS - Skyworks Solutions +2% on in-line Q1, $2B buyback https://seekingalpha.com/news/3429891-skyworks-solutionsplus-2-on-in-line-q1-2b-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3429891-skyworks-solutionsplus-2-on-in-line-q1-2b-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429873\" data-ts=\"1549401765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429873-snapplus-16-after-record-revenue-tops-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap +16% after record revenue tops expectations</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is crackling and popping postmarket, <font color=\"green\">up 16.1%</font>, after its Q4 beat Street expectations for both revenues and earnings.</li>    <li>Daily active users were flat both sequentially and year-over-year, topping forecasts for a decline.</li>    <li>Revenue rose 36% to a record $390M, and operating loss improved by $166M to -$195M.</li>    <li>Net loss improved by $158M to -$192M, and EBITDA loss rose by $109M to -$50M.</li>    <li>DAUs were 186M compared with the prior year's 187M and last quarter's 186M.</li>    <li>The company spent 2018 building long-term scalability, CEO Evan Spiegel says, and \"We ended the year with user engagement stabilizing and have started rolling out the new version of our Android application to a small percentage of our community.\"</li>    <li>\"We are substantially closer to achieving profitability, as we have maintained a relatively flat cost structure across the past five quarters while growing full-year revenue 43 percent year-over-year,\" Spiegel says.</li>    <li>Operating cash flow improved by $50M to -$126M and free cash flow improved by $49M to -$149M.</li>    <li>For Q1, it's guiding to revenue of $285M-$310M (up 24-34%, and in line with expectations for $299.4M) and EBITDA of -$165M to -$140M vs. a year-ago -$218M.</li>    <li><a href=\"http://investor.snap.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429831-snap-beats-0_15-beats-revenue\" target=\"_blank\">Snap beats by $0.15, beats on revenue</a> (Feb. 05 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17402723-snap-inc-announces-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429873\" data-linked=\"Snap +16% after record revenue tops expectations\" data-tweet=\"$SNAP - Snap +16% after record revenue tops expectations https://seekingalpha.com/news/3429873-snapplus-16-after-record-revenue-tops-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3429873-snapplus-16-after-record-revenue-tops-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429862\" data-ts=\"1549401499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFLY\" target=\"_blank\">SFLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429862-shutterfly-reports-mixed-q4-ceo-departure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shutterfly reports mixed Q4, CEO departure</a></h4><ul><li>Shutterfly (NASDAQ:<a href='https://seekingalpha.com/symbol/SFLY' title='Shutterfly, Inc.'>SFLY</a>) reports Q4 results that beat EPS estimates but narrowly missed on revenue despite 60% Y/Y revenue growth. Shares were halted ahead of earnings and will resume trading at 4:30 PMm.</li><li>Downside Q1 guidance has revenue of $317M to $328M (consensus: $331.13M) and EPS of -$2.59 to -$2.49 (consensus: -2.18).</li><li>CEO departure: CEO Christopher North will leave his role at the end of August and the board has hired an executive search firm to find his replacement.</li><li>New committee: The board also formed a Strategic Review Committee and hired a financial advisor to continue the ongoing review of strategic and financial alternatives.</li><li>Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.shutterflyinc.com&amp;esheet=51935908&amp;newsitemid=20190205005943&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.shutterflyinc.com&amp;index=2&amp;md5=8313c276b6d3e4f8c6bf2056db4ee094\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17402668-shutterfly-announces-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429803-shutterfly-beats-0_34-misses-revenue\" target=\"_blank\">Shutterfly beats by $0.34, misses on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429862\" data-linked=\"Shutterfly reports mixed Q4, CEO departure\" data-tweet=\"$SFLY - Shutterfly reports mixed Q4, CEO departure https://seekingalpha.com/news/3429862-shutterfly-reports-mixed-q4-ceo-departure?source=tweet\" data-url=\"https://seekingalpha.com/news/3429862-shutterfly-reports-mixed-q4-ceo-departure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429859\" data-ts=\"1549401466\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429859-amicus-announces-positive-gaa-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus announces positive AT-GAA data</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) <a href=\"https://seekingalpha.com/pr/17402650-amicus-therapeutics-announces-positive-data-pompe-disease-phase-1-2-study-24-months-15th\" target=\"_blank\">announces </a>positive 24-month results from a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02675465?lead=amicus&amp;rank=5\" target=\"_blank\">ATB200-02</a>, evaluating AT-GAA in patients with an inherited lysosomal storage disorder called Pompe disease. The data are being presented at the WORLD<em>Symposium</em> in Orlando, FL.</li><li>Muscle function improved in 94% (n=16/17) of patients who have available data for up to 21 - 24 months (selective use of data here).</li><li>Six-minute walk test (6MWT) distance increased in both enzyme replacement therapy &#40;ERT&#41;-naive and ERT-switch patients with continued benefit observed out to months 21 - 24. Pulmonary function also improved in both groups.</li><li>AT-GAA consists of ATB200, a optimized recombinant human acid alpha-glucosidase enzyme, co-administered with a pharmacological chaperone called AT2221.</li><li>Management will host a webcast for investors and analysts tomorrow, February 6, at 7:00 pm ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429859\" data-linked=\"Amicus announces positive AT-GAA data\" data-tweet=\"$FOLD - Amicus announces positive AT-GAA data https://seekingalpha.com/news/3429859-amicus-announces-positive-gaa-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3429859-amicus-announces-positive-gaa-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429854\" data-ts=\"1549401401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429854-skyworks-solutions-eps-and-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyworks Solutions EPS and revenue in-line</a></h4><ul><li>Skyworks Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>): Q1 Non-GAAP EPS of $1.83 in-line; GAAP EPS of $1.60 <span style=\"color:green\">beats by $0.01</span>.</li><li>Revenue of $972M (-7.4% Y/Y) in-line.</li><li>Shares <font color=\"green\">+2%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17402755-skyworks-reports-q1-fy19-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429854\" data-linked=\"Skyworks Solutions EPS and revenue in-line\" data-tweet=\"$SWKS - Skyworks Solutions EPS and revenue in-line https://seekingalpha.com/news/3429854-skyworks-solutions-eps-and-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3429854-skyworks-solutions-eps-and-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429847\" data-ts=\"1549401376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MXL\" target=\"_blank\">MXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429847-maxlinear-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MaxLinear beats by $0.01, beats on revenue</a></h4><ul><li>MaxLinear (NYSE:<a href='https://seekingalpha.com/symbol/MXL' title='MaxLinear, Inc.'>MXL</a>): Q4 Non-GAAP EPS of $0.20 <span style=\"color:green\">beats by $0.01</span>; GAAP EPS of $0.00 <span style=\"color:green\">beats by $0.20</span>.</li><li>Revenue of $87.63M (-22.9% Y/Y) <font color=\"green\">beats by $0.6M</font>.</li><li>Shares <font color=\"green\">+1.32%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17402693-maxlinear-inc-announces-fourth-quarter-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429847\" data-linked=\"MaxLinear beats by $0.01, beats on revenue\" data-tweet=\"$MXL - MaxLinear beats by $0.01, beats on revenue https://seekingalpha.com/news/3429847-maxlinear-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3429847-maxlinear-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429839\" data-ts=\"1549401264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429839-disneyplus-2-parks-networks-lead-to-q1-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney +2% as parks, networks lead to Q1 beat</a></h4><ul>   <li>Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) is rising after hours, <font color=\"green\">up 2%</font>, after its fiscal Q1 earnings topped expectations on top and bottom lines thanks to continued strength in media networks and theme parks.</li>    <li>Revenues were essentially flat as gains in those areas were offset by lower takes from the film studio and a slightly below flat result in the newly organized direct-to-consumer unit.</li>    <li>Segment operating income, meanwhile, fell 8% and net income dropped 37%.</li>    <li>Excluding some items affecting comparability, mainly prior-year tax benfits, EPS dropped just 3% Y/Y.</li>    <li>\u201cBuilding a robust direct-to-consumer business is our top priority, and we continue to invest in exceptional content and innovative technology to drive our success in this space,\" CEO Bob Iger says.</li>    <li>Revenue by segment: Media Networks, $5.92B (up 7%); Parks, Experiences and Consumer Products, $6.82B (up 5%); Studio Entertainment, $1.82B (down 27%); Direct-to-Consumer and International, $918M (down 1%).</li>    <li>Operating income by segment: Media Networks, $1.33B (up 7%); Parks, Experiences and Consumer Products, $2.15B (up 10%); Studio Entertainment, $309M (down 63%); Direct-to-Consumer and International, -$136M (down from a previous -$42M).</li>    <li><a href=\"http://www.disney.com/investors\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429811-walt-disney-beats-0_30-beats-revenue\" target=\"_blank\">Walt Disney beats by $0.30, beats on revenue</a> (Feb. 05 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17402699-walt-disney-company-reports-first-quarter-earnings-fiscal-2019\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429839\" data-linked=\"Disney +2% as parks, networks lead to Q1 beat\" data-tweet=\"$DIS - Disney +2% as parks, networks lead to Q1 beat https://seekingalpha.com/news/3429839-disneyplus-2-parks-networks-lead-to-q1-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3429839-disneyplus-2-parks-networks-lead-to-q1-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429831\" data-ts=\"1549401100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429831-snap-beats-0_15-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap beats by $0.15, beats on revenue</a></h4><ul><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>): Q4 Non-GAAP EPS of -$0.04 <span style=\"color:green\">beats by $0.15</span>; GAAP EPS of -$0.14 <span style=\"color:green\">beats by $0.05</span>.</li><li>Revenue of $389.82M (+36.4% Y/Y) <font color=\"green\">beats by $12.83M</font>.</li><li>Shares <font color=\"green\">+7.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17402723-snap-inc-announces-fourth-quarter-full-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429831\" data-linked=\"Snap beats by $0.15, beats on revenue\" data-tweet=\"$SNAP - Snap beats by $0.15, beats on revenue https://seekingalpha.com/news/3429831-snap-beats-0_15-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3429831-snap-beats-0_15-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429819\" data-ts=\"1549400907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VREX\" target=\"_blank\">VREX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429819-varex-imaging-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Varex Imaging beats by $0.04, beats on revenue</a></h4><ul><li>Varex Imaging (NASDAQ:<a href='https://seekingalpha.com/symbol/VREX' title='Varex Imaging Corporation'>VREX</a>): Q1 Non-GAAP EPS of $0.26 <span style=\"color:green\">beats by $0.04</span>; GAAP EPS of $0.08 <span style=\"color:red\">misses by $0.10</span>.</li><li>Revenue of $185.7M (+5.4% Y/Y) <font color=\"green\">beats by $8.97M</font>.</li><li>Shares <font color=\"green\">+1.65%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17402648-varex-imaging-announces-financial-results-first-quarter-fiscal-year-2019\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429819\" data-linked=\"Varex Imaging beats by $0.04, beats on revenue\" data-tweet=\"$VREX - Varex Imaging beats by $0.04, beats on revenue https://seekingalpha.com/news/3429819-varex-imaging-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3429819-varex-imaging-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429814\" data-ts=\"1549400855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DATA\" target=\"_blank\">DATA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429814-tableau-software-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tableau Software beats by $0.05, beats on revenue</a></h4><ul><li>Tableau Software (NYSE:<a href='https://seekingalpha.com/symbol/DATA' title='Tableau Software'>DATA</a>): Q4 Non-GAAP EPS of -$0.03 <font color=\"green\">beats by $0.05</font>; GAAP EPS of $0.03.</li><li>Revenue of $275.7M (+10.6% Y/Y) <font color=\"green\">beats by $3.69M</font>.</li><li>Shares <font color=\"green\">+1.8%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17402695-tableau-reports-q4-full-year-2018-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429814\" data-linked=\"Tableau Software beats by $0.05, beats on revenue\" data-tweet=\"$DATA - Tableau Software beats by $0.05, beats on revenue https://seekingalpha.com/news/3429814-tableau-software-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3429814-tableau-software-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429793\" data-ts=\"1549400032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVA\" target=\"_blank\">CVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429793-covanta-upgraded-to-buy-goldman-on-u-k-project-pipeline-catalysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Covanta upgraded to Buy at Goldman on U.K. project pipeline catalysts</a></h4><ul><li>Covanta (<a href='https://seekingalpha.com/symbol/CVA' title='Covanta Holding Corporation'>CVA</a> <font color='green'>+4.9%</font>) climbs to its highest level in five months after Goldman Sachs <a href=\"https://thefly.com/thestreet/realmoney/index.php/CVAid2858824/CVA-Goldman-Sachs-upgrades-Covanta-to-Buy-boosts-target-to-\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $19 price target, raised from $16.50, as the firm expects near-term U.K. project pipeline catalysts to highlight the company's medium- to long-term growth potential.</li><li>CVA's mix shift away from energy towards waste \"augurs well for buffeting cyclical risk,\" and the stock's current valuation is attractive, Goldman analyst Brian Lee writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429793\" data-linked=\"Covanta upgraded to Buy at Goldman on U.K. project pipeline catalysts\" data-tweet=\"$CVA - Covanta upgraded to Buy at Goldman on U.K. project pipeline catalysts https://seekingalpha.com/news/3429793-covanta-upgraded-to-buy-goldman-on-u-k-project-pipeline-catalysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3429793-covanta-upgraded-to-buy-goldman-on-u-k-project-pipeline-catalysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429791\" data-ts=\"1549399331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429791-biolinerx-down-41-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx down 41% on equity offering</a></h4><ul><li>Thinly traded nano cap BioLineRx (<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color=\"red\">-40.7%</font>) is down on a healthy 40x surge in volume in reaction to its <a href=\"https://seekingalpha.com/pr/17402016-biolinerx-announces-pricing-15_4-million-underwritten-public-offering-american-depositary\" target=\"_blank\">public offering</a> of 28M American Depositary Shares (ADSs) at $0.55 per share plus five-year warrants to purchase up to the same number of ADSs at $0.75. Gross proceeds should be $15.4M.</li><li>Yesterday's close was $0.73.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429791\" data-linked=\"BioLineRx down 41% on equity offering\" data-tweet=\"$BLRX - BioLineRx down 41% on equity offering https://seekingalpha.com/news/3429791-biolinerx-down-41-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3429791-biolinerx-down-41-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429790\" data-ts=\"1549398932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429790-pulmatrix-down-8-on-planned-reverse-split\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix down 8% on planned reverse split</a></h4><ul><li>Aimed at regaining compliance with Nasdaq's minimum bid price listing requirement, Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color=\"red\">-8.2%</font>) will <a href=\"https://seekingalpha.com/pr/17402472-pulmatrix-inc-announces-1minus-10-reverse-stock-split\" target=\"_blank\">execute </a>a 1:10 reverse split of its common stock after the close. Post-split trading will commence tomorrow, February 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429790\" data-linked=\"Pulmatrix down 8% on planned reverse split\" data-tweet=\"$PULM - Pulmatrix down 8% on planned reverse split https://seekingalpha.com/news/3429790-pulmatrix-down-8-on-planned-reverse-split?source=tweet\" data-url=\"https://seekingalpha.com/news/3429790-pulmatrix-down-8-on-planned-reverse-split\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429785\" data-ts=\"1549398139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPTX\" target=\"_blank\">LPTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429785-leap-closes-13_2m-capital-raise-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leap closes $13.2M capital raise; shares up 4%</a></h4><ul><li>Leap Therapeutics (<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics'>LPTX</a> <font color=\"green\">+4.3%</font>) has <a href=\"https://seekingalpha.com/pr/17402521-leap-therapeutics-announces-closing-public-offering-full-exercise-underwriters-option\" target=\"_blank\">closed</a> its public offering of ~6.6M common shares and warrants to purchase up to the same number of shares. Underwriters exercised their option to buy an additional ~986K shares. Gross proceeds were ~$13.2M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429785\" data-linked=\"Leap closes $13.2M capital raise; shares up 4%\" data-tweet=\"$LPTX - Leap closes $13.2M capital raise; shares up 4% https://seekingalpha.com/news/3429785-leap-closes-13_2m-capital-raise-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3429785-leap-closes-13_2m-capital-raise-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429781\" data-ts=\"1549397286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429781-t-mobile-taps-rochester-area-for-second-major-customer-center\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">T-Mobile taps Rochester area for second major customer center</a></h4><ul>   <li>T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color=\"red\">-2.9%</font>) and Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color=\"red\">-4.6%</font>) are naming the area of Rochester, N.Y., as the <a href=\"https://seekingalpha.com/pr/17402579-t-mobile-sprint-announce-new-york-state-second-location-customer-experience-center-serve-new\" target=\"_blank\">second location</a> for one of their <a href=\"https://seekingalpha.com/news/3427560-t-mobile-sprint-plan-5600-jobs-via-new-customer-centers\" target=\"_blank\">five new customer experience centers</a>.</li>    <li>That means at least 1,000 new jobs, conditioned on the approval of their proposed merger.</li>    <li>The companies have planned up to 5,600 new jobs across the five centers. T-Mobile says that using its Team of Experts model, it will employ 7,500 more customer care professionals in 2024 than the stand-alone companies would be employing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429769-new-street-t-mobile-price-pledge-points-merger-approval-problems\" target=\"_blank\">New Street: T-Mobile price pledge points to merger approval problems</a> (Feb. 05 2019)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429781\" data-linked=\"T-Mobile taps Rochester area for second major customer center\" data-tweet=\"$TMUS $TMUS $S - T-Mobile taps Rochester area for second major customer center https://seekingalpha.com/news/3429781-t-mobile-taps-rochester-area-for-second-major-customer-center?source=tweet\" data-url=\"https://seekingalpha.com/news/3429781-t-mobile-taps-rochester-area-for-second-major-customer-center\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429779\" data-ts=\"1549396924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSH\" target=\"_blank\">VSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429779-gluu-box-and-oibr-c-among-notable-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GLUU, BOX and OIBR.C among notable tech movers</a></h4><ul><li><strong>Gainers: </strong>Vishay Intertechnology (NYSE:<a href='https://seekingalpha.com/symbol/VSH' title='Vishay Intertechnology Inc.'>VSH</a>) <font color=\"green\">+11%</font>. Oi S.A. (NYSE:<a href='https://seekingalpha.com/symbol/OIBR.C' title='Oi S.A. ADR'>OIBR.C</a>) <font color=\"green\">+9%</font>. CDK Global (NYSEARCA:<a href='https://seekingalpha.com/symbol/CDK' title='CDK Global, Inc'>CDK</a>) <font color=\"green\">+10%</font>. Allot (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLT' title='Allot Communications Ltd.'>ALLT</a>) <font color=\"green\">+9%</font>. Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) <font color=\"green\">+9%</font>.</li> <li><strong>Losers: </strong>Control4 (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRL' title='Control4 Corporation'>CTRL</a>) <font color=\"red\">-18%</font>. Glu Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/GLUU' title='Glu Mobile Inc.'>GLUU</a>) <font color=\"red\">-14%</font>. Frequency Electronics (NASDAQ:<a href='https://seekingalpha.com/symbol/FEIM' title='Frequency Electronics, Inc.'>FEIM</a>) <font color=\"red\">-9%</font>. Harmonic (NASDAQ:<a href='https://seekingalpha.com/symbol/HLIT' title='Harmonic Inc.'>HLIT</a>) <font color=\"red\">-8%</font>. FTE Networks (NYSEMKT:<a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a>) <font color=\"red\">-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429779\" data-linked=\"GLUU, BOX and OIBR.C among notable tech movers\" data-tweet=\"$VSH $VSH $OIBR.C - GLUU, BOX and OIBR.C among notable tech movers https://seekingalpha.com/news/3429779-gluu-box-and-oibr-c-among-notable-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429779-gluu-box-and-oibr-c-among-notable-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429777\" data-ts=\"1549395803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429777-ges-french-jobs-fine-only-tip-of-power-woes-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE&#39;s French jobs fine only the tip of power woes - Bloomberg</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color=\"green\">+3%</font>) <a href=\"https://seekingalpha.com/news/3429622-france-fines-ge-57m-missing-target-promised-job-creation\" target=\"_blank\">owes the French government a $57M fine</a> for falling short on a jobs pledge, but there's <a href=\"https://www.bloomberg.com/opinion/articles/2019-02-05/ge-s-french-jobs-fine-is-only-tip-of-power-woes\" target=\"_blank\">much more restructuring work and associated costs ahead</a>, Bloomberg's Brooke Sutherland writes.</li><li>GE already has taken ~$6B in restructuring and other charges net of tax for 2017-18 combined, with most coming from the power division, \"and it\u2019s far from done,\" Sutherland says, as CEO Larry Culp has said increased restructuring expenses at both the power unit and corporate headquarters will weigh on cash flow this year.</li><li>GE's industrial cash flow likely will decline significantly in 2019, perhaps even dipping into negative territory, and the company likely will need aggressive restructuring over multiple years to get  its power unit functioning at a more sustainable capacity, Sutherland says.</li><li>\"The agreement with the French government reflects one of GE\u2019s biggest  hurdles on this front: It's just not that easy to close large factories  and fire loads of people, especially in Europe,\" Sutherland writes, which likely  will temper any cash flow recovery in the power unit, which reported a $2.7B outflow last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429777\" data-linked=\"GE&#39;s French jobs fine only the tip of power woes - Bloomberg\" data-tweet=\"$GE - GE&#39;s French jobs fine only the tip of power woes - Bloomberg https://seekingalpha.com/news/3429777-ges-french-jobs-fine-only-tip-of-power-woes-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3429777-ges-french-jobs-fine-only-tip-of-power-woes-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>90&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429769\" data-ts=\"1549394964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMUS\" target=\"_blank\">TMUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429769-new-street-t-mobile-price-pledge-points-to-merger-approval-problems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Street: T-Mobile price pledge points to merger approval problems</a></h4><ul>   <li>A promise from T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color=\"red\">-2.7%</font>) to <a href=\"https://seekingalpha.com/news/3429367-t-mobile-prices-go-sprint-merger\" target=\"_blank\">keep prices where they're at</a> or better for three years after a Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color=\"red\">-4.1%</font>) merger points to a potential problem in the deal, New Street Research says.</li>    <li>Simply put, such a promise from T-Mobile chief John Legere shows the government has specific concerns about price impact from the merger. If the deal doesn't harm competition as T-Mobile and Sprint are arguing, why make the pledge? (h/t Bloomberg)</li>    <li>The firm says based on current antitrust policy that the DOJ can't rely on post-approval conditions, it's unlikely that the antitrust division will sign off.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429769\" data-linked=\"New Street: T-Mobile price pledge points to merger approval problems\" data-tweet=\"$TMUS $TMUS $S - New Street: T-Mobile price pledge points to merger approval problems https://seekingalpha.com/news/3429769-new-street-t-mobile-price-pledge-points-to-merger-approval-problems?source=tweet\" data-url=\"https://seekingalpha.com/news/3429769-new-street-t-mobile-price-pledge-points-to-merger-approval-problems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429768\" data-ts=\"1549394945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429768-etsyplus-6-after-keybanc-points-to-positive-spending-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy +6% after KeyBanc points to positive spending trends</a></h4><ul><li>Etsy (NASDAQ:<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a>) <font color=\"green\">rallies 5.7%</font> after KeyBanc analyst Edward Yruma tips that early proprietary card data showed an acceleration in January spending trends.</li><li>Shares of Etsy carved out a new all-time high of $60.57 earlier in the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429768\" data-linked=\"Etsy +6% after KeyBanc points to positive spending trends\" data-tweet=\"$ETSY - Etsy +6% after KeyBanc points to positive spending trends https://seekingalpha.com/news/3429768-etsyplus-6-after-keybanc-points-to-positive-spending-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3429768-etsyplus-6-after-keybanc-points-to-positive-spending-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429761\" data-ts=\"1549394682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPRK\" target=\"_blank\">GPRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429761-geoparkplus-8-year-end-pdp-reserves-rise-55\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GeoPark +8% as year-end PDP reserves rise 55%</a></h4><ul><li>GeoPark (<a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a> <font color='green'>+7.7%</font>) jumps to a four-month high after announcing an independent <a href=\"https://seekingalpha.com/pr/17401413-geopark-announces-2018-certified-oil-gas-reserves\" target=\"_blank\">oil and gas reserves assessment</a> as of year-end 2018.</li><li>GPRK reports net proven developed producing reserves jumped 55% to 44.2M boe, net proven reserves increased +17% to 113.9M boe and net proven and probable reserves gained +15% to 183.7Mboe.</li><li>GPRK says it achieved record production in Colombia of 10.8M bbl in 2018, up 30% Y/Y, and 2P D&amp;M certified reserves rose 26% to 111.2M bbl due to strong reservoir performance and continued successful exploration, development and appraisal drilling in the Llanos 34 block.</li><li>CEO James Park says the \"Colombian Llanos 34 prize keeps getting more massive with even more opportunity for expansion\" and that \"every category of reserve was certified with significant increases.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3429761\" data-linked=\"GeoPark +8% as year-end PDP reserves rise 55%\" data-tweet=\"$GPRK - GeoPark +8% as year-end PDP reserves rise 55% https://seekingalpha.com/news/3429761-geoparkplus-8-year-end-pdp-reserves-rise-55?source=tweet\" data-url=\"https://seekingalpha.com/news/3429761-geoparkplus-8-year-end-pdp-reserves-rise-55\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429738\" data-ts=\"1549393102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429738-amyris-and-aceto-among-energy-materials-gainers-magnegas-applied-technology-solutions-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris and Aceto among Energy/Materials gainers; MagneGas Applied Technology Solutions and Cabot among losers</a></h4><ul><li><b>Gainers: </b>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+61%</font>. Aceto (NASDAQ:<a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a>) <font color=\"green\">+15%</font>. GeoPark (NYSE:<a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a>) <font color=\"green\">+9%</font>. Calumet Specialty Products Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+8%</font>. Olin (NYSE:<a href='https://seekingalpha.com/symbol/OLN' title='Olin Corporation'>OLN</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>MagneGas Applied Technology Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a>) <font color=\"red\">-9%</font>. Cabot (NYSE:<a href='https://seekingalpha.com/symbol/CBT' title='Cabot Corporation'>CBT</a>) <font color=\"red\">-8%</font>. Pioneer Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a>) <font color=\"red\">-8%</font>. SunCoke Energy (NYSE:<a href='https://seekingalpha.com/symbol/SXC' title='SunCoke Energy'>SXC</a>) <font color=\"red\">-8%</font>. NCS Multistage (NASDAQ:<a href='https://seekingalpha.com/symbol/NCSM' title='NCS Multistage Holdings'>NCSM</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429738\" data-linked=\"Amyris and Aceto among Energy/Materials gainers; MagneGas Applied Technology Solutions and Cabot among losers\" data-tweet=\"$AMRS $AMRS $ACET - Amyris and Aceto among Energy/Materials gainers; MagneGas Applied Technology Solutions and Cabot among losers https://seekingalpha.com/news/3429738-amyris-and-aceto-among-energy-materials-gainers-magnegas-applied-technology-solutions-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3429738-amyris-and-aceto-among-energy-materials-gainers-magnegas-applied-technology-solutions-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429725\" data-ts=\"1549391470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPWK\" target=\"_blank\">UPWK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429725-upwork-joins-hedgeyes-best-idea-long-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upwork joins Hedgeye&#39;s Best Idea Long list</a></h4><ul><li>Hedgeye names Upwork (NASDAQ:<a href='https://seekingalpha.com/symbol/UPWK' title='Upwork'>UPWK</a>) as a new Best Idea Long calling the company \"a mostly untapped, expanding opportunity.\"</li><li>The firm says Upwork investors could see 10-fold returns in the long-term.</li><li>Upwork shares are <font color=\"green\">up 3.6%</font> to $19.67.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429725\" data-linked=\"Upwork joins Hedgeye&#39;s Best Idea Long list\" data-tweet=\"$UPWK - Upwork joins Hedgeye&#39;s Best Idea Long list https://seekingalpha.com/news/3429725-upwork-joins-hedgeyes-best-idea-long-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3429725-upwork-joins-hedgeyes-best-idea-long-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429712\" data-ts=\"1549390204\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429712-boeing-to-invest-in-supersonic-jet-developer-aerion-shares-up-another-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing to invest in supersonic jet developer Aerion; shares up another 2%</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"green\">+2.3%</font>) says it made a <a href=\"https://seekingalpha.com/pr/17402381-boeing-partners-aerion-accelerate-supersonic-travel\" target=\"_blank\">\"significant\" but undisclosed investment</a> in supersonic aircraft developer Aerion in an attempt to accelerate technology development and aircraft design.</li><li>Boeing says it will provide engineering, manufacturing and flight test services for Aerion\u2019s <a href=\"https://www.reuters.com/article/us-boeing-aerion/boeing-makes-significant-investment-in-supersonic-jet-developer-aerion-idUSKCN1PU1YW\" target=\"_blank\">$120M AS2 supersonic business jet,</a> whose first flight is scheduled for 2023.</li><li>The AS2 is designed to fly at speeds up to Mach 1.4, or ~1K miles/hour, with the ability to fly as much as 70% faster than today's business jets.</li><li>BA shares power past $400 for the first time and are poised for a second-straight record closing high.</li><li><a href=\"https://seekingalpha.com/news/3429346-boeing-shares-bull-another-record-bucking-china-slowdown-concerns\" target=\"_blank\">Earlier</a>: Boeing shares bull to another record, bucking China slowdown concerns (Feb. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429712\" data-linked=\"Boeing to invest in supersonic jet developer Aerion; shares up another 2%\" data-tweet=\"$BA - Boeing to invest in supersonic jet developer Aerion; shares up another 2% https://seekingalpha.com/news/3429712-boeing-to-invest-in-supersonic-jet-developer-aerion-shares-up-another-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3429712-boeing-to-invest-in-supersonic-jet-developer-aerion-shares-up-another-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429711\" data-ts=\"1549390202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLNE\" target=\"_blank\">HLNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429711-dunxin-financial-holdings-leads-financial-gainers-proassurance-and-lazard-only-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dunxin Financial Holdings leads financial gainers; ProAssurance and Lazard only losers</a></h4><ul><li><b>Gainers: </b>Dunxin Financial Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DXF' title='Dunxin Financial Holdings Limited'>DXF</a>) <font color=\"green\">+7%</font>. Hamilton Lane (NASDAQ:<a href='https://seekingalpha.com/symbol/HLNE' title='Hamilton Lane Inc'>HLNE</a>) <font color=\"green\">+7%</font>. China Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='China Commercial Credit, Inc.'>GLG</a>) <font color=\"green\">+6%</font>. Firsthand Technology Value Fund (NASDAQ:<a href='https://seekingalpha.com/symbol/SVVC' title='Firsthand Technology Value Fund'>SVVC</a>) <font color=\"green\">+6%</font>. Kingsway Financial Services (NYSE:<a href='https://seekingalpha.com/symbol/KFS' title='Kingsway Financial Services Inc'>KFS</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>ProAssurance (NYSE:<a href='https://seekingalpha.com/symbol/PRA' title='ProAssurance Corporation'>PRA</a>) <font color=\"red\">-6%</font>. Lazard (NYSE:<a href='https://seekingalpha.com/symbol/LAZ' title='Lazard Ltd.'>LAZ</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429711\" data-linked=\"Dunxin Financial Holdings leads financial gainers; ProAssurance and Lazard only losers\" data-tweet=\"$HLNE $DXF $HLNE - Dunxin Financial Holdings leads financial gainers; ProAssurance and Lazard only losers https://seekingalpha.com/news/3429711-dunxin-financial-holdings-leads-financial-gainers-proassurance-and-lazard-only-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429711-dunxin-financial-holdings-leads-financial-gainers-proassurance-and-lazard-only-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429703\" data-ts=\"1549389720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALIM\" target=\"_blank\">ALIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429703-alimeras-iluvien-okd-in-lebanon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alimera&#39;s Iluvien OK&#39;d in Lebanon</a></h4><ul><li>Lebanon's Ministry of Health has <a href=\"https://seekingalpha.com/pr/17401485-alimera-sciences-announces-approval-iluvien-r-lebanon\" target=\"_blank\">approved </a>Alimera Sciences' (<a href='https://seekingalpha.com/symbol/ALIM' title='Alimera Sciences, Inc.'>ALIM</a> <font color=\"green\">+5.3%</font>) ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema in patients who have previously received corticosteroid therapy and did not have a significant rise in intraocular pressure.</li><li>MEAgate will distribute.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429703\" data-linked=\"Alimera&#39;s Iluvien OK&#39;d in Lebanon\" data-tweet=\"$ALIM - Alimera&#39;s Iluvien OK&#39;d in Lebanon https://seekingalpha.com/news/3429703-alimeras-iluvien-okd-in-lebanon?source=tweet\" data-url=\"https://seekingalpha.com/news/3429703-alimeras-iluvien-okd-in-lebanon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429697\" data-ts=\"1549389313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429697-fda-tentatively-oks-tevas-generic-farxiga-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA tentatively OKs Teva&#39;s generic Farxiga; shares up 2%</a></h4><ul><li>The FDA has <a href=\"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=211541\" target=\"_blank\">tentatively approved</a> Teva Pharmaceutical Industries' (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+1.8%</font>) generic version of AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color=\"green\">+0.9%</font>) type 2 diabetes med FARXIGA (dapagliflozin).</li><li>Tentative approval means that the application met the criteria for approval but patent issues need to be resolved before the product can be sold in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429697\" data-linked=\"FDA tentatively OKs Teva&#39;s generic Farxiga; shares up 2%\" data-tweet=\"$TEVA $AZN - FDA tentatively OKs Teva&#39;s generic Farxiga; shares up 2% https://seekingalpha.com/news/3429697-fda-tentatively-oks-tevas-generic-farxiga-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3429697-fda-tentatively-oks-tevas-generic-farxiga-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429693\" data-ts=\"1549388879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPGN\" target=\"_blank\">OPGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429693-opgen-completes-studies-to-support-acuitas-gene-panel-filing-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OpGen completes studies to support Acuitas gene panel filing; shares up 4%</a></h4><ul><li>Thinly traded nano cap OpGen (<a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color=\"green\">+3.5%</font>) is up on modestly higher volume, albeit on turnover of only 166K shares, following its <a href=\"https://seekingalpha.com/pr/17401481-opgen-completes-clinical-trials-initial-fda-510-k-submission\" target=\"_blank\">announcement </a>that it has completed the clinical studies needed to support its U.S. 510(k) submission seeking clearance for it Acuitas AMR Gene Panel u5.47 product.</li><li>The company says the panel detects five key pathogens and 47 antibiotic-resistance genes covering nine antibiotic classes in less than three hours using bacterial isolates.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429693\" data-linked=\"OpGen completes studies to support Acuitas gene panel filing; shares up 4%\" data-tweet=\"$OPGN - OpGen completes studies to support Acuitas gene panel filing; shares up 4% https://seekingalpha.com/news/3429693-opgen-completes-studies-to-support-acuitas-gene-panel-filing-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3429693-opgen-completes-studies-to-support-acuitas-gene-panel-filing-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429677\" data-ts=\"1549387829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNCR\" target=\"_blank\">XNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429677-xencor-up-4-on-roche-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xencor up 4% on Roche deal</a></h4><ul><li>Thinly traded Xencor (<a href='https://seekingalpha.com/symbol/XNCR' title='Xencor, Inc.'>XNCR</a> <font color=\"green\">+3.5%</font>) is up below-average volume in response to its license <a href=\"https://seekingalpha.com/pr/17401674-xencor-develop-commercialize-novel-ilminus-15-immune-activating-cytokines-genentech\" target=\"_blank\">agreement </a>with Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color=\"green\">+0.6%</font>) Genentech aimed at developing and commercializing novel IL-15 cytokine therapeutics, including XNCR's XmAb24306.</li><li>XNCR says the partnership will accelerate its efforts in immuno-oncology via the exploration of new combinations of XmAb24306 with Genentech drugs.</li><li>IL-15 is an immune system-stoking protein that activates natural killer cells and anti-cancer T cells while minimizing regulatory T cell activation compared to IL-2 (in other words, it minimizes the potential immune response to the therapy).</li><li>Under the terms of the partnership, Genentech will pay XNCR $120M upfront, up to $160M in milestones for the XmAb24306 program and up to $180M in milestones for each new IL-15 candidate.</li><li>The companies will co-develop XmAb24306 and other programs where they shares development costs and profits. Genentech owns global commercialization rights while XNCR has the option to co-promote in the U.S. They will also collaborate in a two-year research program to discover new IL-15 candidates, including ones targeting specific immune cell populations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429677\" data-linked=\"Xencor up 4% on Roche deal\" data-tweet=\"$XNCR $RHHBY - Xencor up 4% on Roche deal https://seekingalpha.com/news/3429677-xencor-up-4-on-roche-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3429677-xencor-up-4-on-roche-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429672\" data-ts=\"1549387368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSWI\" target=\"_blank\">CSWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429672-csw-industrialsplus-3-post-q3-results-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CSW Industrials +3% post Q3 results beat</a></h4><div><ul><li>CSW Industrials (<a href='https://seekingalpha.com/symbol/CSWI' title='CSW Industrials, Inc.'>CSWI</a> <font color=\"green\">+3.8%</font>) reported Q3 revenue growth of 12.2% Y/Y to $77.5M, driven by increased sales in both the segments Industrial Products $43.65M (+15.2% Y/Y) and Specialty Chemicals $33.84M (+8.7% Y/Y).</li><li>Q3 Gross margin <font color=\"green\">improved by 41 bps</font> to 44.2%; and operating margin <font color=\"green\">improved by 66 bps</font> to 12.2%.</li><li>Segment operating margins: Industrial Products 18.5% <font color=\"red\">down by 80 bps</font>; and Specialty Chemicals 13.5% <font color=\"green\">up by 100 bps</font>.</li><li>SG&amp;A expenses were $23.81M (+11.4% Y/Y) and margin was 32% <font color=\"green\">down by 24 bps</font>.</li><li>Operating cash flow from continuing operations YTD was $58.3M, compared to of $47.1M a year ago.</li><li>Company has Cash and cash equivalents of $14.62M, as of December 31, 2018.</li><li>Company returned $9.9M to shareholders through share repurchases during the quarter, bringing the year-to-date total to $40.7M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429514-csw-industrials-beats-0_05-beats-revenue\" target=\"_blank\">CSW Industrials beats by $0.05, beats on revenue</a> (Feb. 5)</li></ul></div><div class=\"tiny-share-widget\" data-id=\"3429672\" data-linked=\"CSW Industrials +3% post Q3 results beat\" data-tweet=\"$CSWI - CSW Industrials +3% post Q3 results beat https://seekingalpha.com/news/3429672-csw-industrialsplus-3-post-q3-results-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3429672-csw-industrialsplus-3-post-q3-results-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429664\" data-ts=\"1549386848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGX\" target=\"_blank\">AGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429664-argans-gemma-power-inks-epc-contract-to-build-1_8-gw-power-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argan&#39;s Gemma Power inks EPC contract to build 1.8 GW power project</a></h4><ul><li>Argan (<a href='https://seekingalpha.com/symbol/AGX' title='Argan, Inc.'>AGX</a> <font color='green'>+11.1%</font>) jumps to a 52-week high following news that its wholly-owned Gemma Power Systems subsidiary signed an engineering, procurement and construction services contract to <a href=\"http://arganinc.com/wp-content/uploads/2019/02/AGX_Press-Release_Guernsey_FINAL_2.5.19.pdf\" target=\"_blank\">build a 1,875 MW natural gas-fired power plant</a> in Guernsey County, Ohio, with completion expected in 2022.</li><li>AGX says the signing of the project and receipt of the related limited notice to proceed with preliminary design and site preparation activities help lift its project backlog to more than $1B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429664\" data-linked=\"Argan&#39;s Gemma Power inks EPC contract to build 1.8 GW power project\" data-tweet=\"$AGX - Argan&#39;s Gemma Power inks EPC contract to build 1.8 GW power project https://seekingalpha.com/news/3429664-argans-gemma-power-inks-epc-contract-to-build-1_8-gw-power-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3429664-argans-gemma-power-inks-epc-contract-to-build-1_8-gw-power-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429663\" data-ts=\"1549386832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429663-vmware-acquires-remote-support-solution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VMware acquires remote support solution</a></h4><ul><li>VMware (<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a> <font color='green'>+1.6%</font>) <a href=\"https://blogs.vmware.com/euc/2019/02/advanced-remote-management.html\" target=\"_blank\">will acquire </a>remote support solution provider AetherPal for undisclosed terms. AetherPal's employees will join VMW's End User Computing team.</li><li>VMware has resold AetherPal's Remote Support solution as a Workspace ONE add-on since 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429663\" data-linked=\"VMware acquires remote support solution\" data-tweet=\"$VMW - VMware acquires remote support solution https://seekingalpha.com/news/3429663-vmware-acquires-remote-support-solution?source=tweet\" data-url=\"https://seekingalpha.com/news/3429663-vmware-acquires-remote-support-solution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429660\" data-ts=\"1549386750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETTX\" target=\"_blank\">ETTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429660-entasis-on-go-late-stage-study-of-lead-antibiotic-candidate-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Entasis on go with late-stage study of lead antibiotic candidate; shares up 4%</a></h4><ul><li>Based on FDA feedback during an End-of-Phase 2 meeting, Entasis Therapeutics (<a href='https://seekingalpha.com/symbol/ETTX' title='Entasis Therapeutics'>ETTX</a> <font color=\"green\">+3.6%</font>) plans to <a href=\"https://seekingalpha.com/pr/17401561-entasis-therapeutics-receives-positive-feedback-fda-end-phase-2-meeting-etx2514sul-signs\" target=\"_blank\">launch</a> a Phase 3 study this quarter evaluating lead candidate ETX2514SUL in patients with pneumonia and bloodstream infections caused by carbapenem-resistant <em>Acinetobacter baumannii</em>, a Gram-negative bacterium associated with high mortality.</li><li>The company says <a href=\"http://www.entasistx.com/pipeline\" target=\"_blank\">ETX2514SUL</a> is a novel, broad-spectrum inhibitor of class A, C, and D β-lactamases, enzymes produced by bacteria that enable them to resist β-lactam antibiotics.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429660\" data-linked=\"Entasis on go with late-stage study of lead antibiotic candidate; shares up 4%\" data-tweet=\"$ETTX - Entasis on go with late-stage study of lead antibiotic candidate; shares up 4% https://seekingalpha.com/news/3429660-entasis-on-go-late-stage-study-of-lead-antibiotic-candidate-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3429660-entasis-on-go-late-stage-study-of-lead-antibiotic-candidate-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429658\" data-ts=\"1549386231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429658-tech-sees-green-despite-rocky-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech sees green despite rocky earnings</a></h4><ul><li>The tech sector is <font color=\"green\">up 0.9% </font>despite investor <a href=\"https://seekingalpha.com/news/3429545-alphabet-targets-trimmed-margin-capex\" target=\"_blank\">concerns</a> with Alphabet's operating margin and capex, Seagate's mixed Q2 with <a href=\"https://seekingalpha.com/news/3429568-seagate-guides-downside-q3\" target=\"_blank\">downside guidance</a>, and Lumentum's<a href=\"https://seekingalpha.com/news/3429495-lumentum-minus-5-percent-eps-miss\" target=\"_blank\"> EPS miss</a>. The market is optimistic ahead of President Trump's State of the Union address, which is expected to promote unity.</li><li>The Philadelphia Semiconductor Index is <font color=\"green\">up 0.4%</font> and the tech-heavy Nasdaq 100 is <font color=\"green\">up 0.8%</font>.</li><li>Related broad tech ETFs: <a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>, <a href='https://seekingalpha.com/symbol/VGT' title='Vanguard Information Technology ETF'>VGT</a>, <a href='https://seekingalpha.com/symbol/TECL' title='Direxion Technology Bull 3x Shares ETF'>TECL</a>, <a href='https://seekingalpha.com/symbol/FTEC' title='Fidelity MSCI Information Technology Index ETF'>FTEC</a>, <a href='https://seekingalpha.com/symbol/IYW' title='iShares U.S. Technology ETF'>IYW</a>, <a href='https://seekingalpha.com/symbol/ROM' title='ProShares Ultra Technology ETF'>ROM</a>, <a href='https://seekingalpha.com/symbol/QTEC' title='First Trust NASDAQ-100-Tech Index ETF'>QTEC</a>, <a href='https://seekingalpha.com/symbol/RYT' title='Invesco S&P 500 Equal Weight Technology ETF'>RYT</a>, <a href='https://seekingalpha.com/symbol/FNG' title='AdvisorShares New Tech and Media ETF'>FNG</a>, <a href='https://seekingalpha.com/symbol/TECS' title='Direxion Technology Bear 3x Shares ETF'>TECS</a>, <a href='https://seekingalpha.com/symbol/IGM' title='iShares North American Tech ETF'>IGM</a>, <a href='https://seekingalpha.com/symbol/FXL' title='First Trust Tech AlphaDEX ETF'>FXL</a>, <a href='https://seekingalpha.com/symbol/XNTK' title='SPDR NYSE Technology ETF'>XNTK</a>, <a href='https://seekingalpha.com/symbol/REW' title='ProShares UltraShort Technology ETF'>REW</a>, <a href='https://seekingalpha.com/symbol/JHMT' title='John Hancock Multifactor Technology ETF'>JHMT</a>, <a href='https://seekingalpha.com/symbol/XITK' title='SPDR Innovative Technology ETF'>XITK</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3429658\" data-linked=\"Tech sees green despite rocky earnings\" data-tweet=\"$XLK $VGT $TECL - Tech sees green despite rocky earnings https://seekingalpha.com/news/3429658-tech-sees-green-despite-rocky-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3429658-tech-sees-green-despite-rocky-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429657\" data-ts=\"1549386218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EL\" target=\"_blank\">EL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429657-estee-lauder-leads-consumer-gainers-church-dwight-and-westport-fuel-systems-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Estee Lauder leads consumer gainers; Church &amp; Dwight and Westport Fuel Systems among losers</a></h4><ul><li><b>Gainers: </b>The Estee Lauder (NYSE:<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a>) <font color=\"green\">+12%</font>. Leggett &amp; Platt (NYSE:<a href='https://seekingalpha.com/symbol/LEG' title='Leggett & Platt Inc.'>LEG</a>) <font color=\"green\">+10%</font>. Ralph Lauren (NYSE:<a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a>) <font color=\"green\">+7%</font>. e.l.f. Beauty (NYSE:<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty'>ELF</a>) <font color=\"green\">+6%</font>. Liberty TripAdvisor (NASDAQ:<a href='https://seekingalpha.com/symbol/LTRPA' title='Liberty TripAdvisor Holdings A'>LTRPA</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Church &amp; Dwight (NYSE:<a href='https://seekingalpha.com/symbol/CHD' title='Church & Dwight Co Inc.'>CHD</a>) <font color=\"red\">-8%</font>. Westport Fuel Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a>) <font color=\"red\">-8%</font>. National Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a>) <font color=\"red\">-7%</font>. Archer-Daniels-Midland (NYSE:<a href='https://seekingalpha.com/symbol/ADM' title='Archer Daniels Midland Co.'>ADM</a>) <font color=\"red\">-6%</font>. Coffee Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/JVA' title='Coffee Holding Co., Inc'>JVA</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429657\" data-linked=\"Estee Lauder leads consumer gainers; Church &amp; Dwight and Westport Fuel Systems among losers\" data-tweet=\"$EL $EL $LEG - Estee Lauder leads consumer gainers; Church &amp; Dwight and Westport Fuel Systems among losers https://seekingalpha.com/news/3429657-estee-lauder-leads-consumer-gainers-church-dwight-and-westport-fuel-systems-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429657-estee-lauder-leads-consumer-gainers-church-dwight-and-westport-fuel-systems-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429652\" data-ts=\"1549385559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORT\" target=\"_blank\">CORT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429652-corcept-issues-rebuttal-to-short-sellers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corcept issues rebuttal to short-sellers</a></h4><ul><li>In what it calls a <a href=\"https://www.sec.gov/Archives/edgar/data/1088856/000119312519027646/d625461dex991.htm\" target=\"_blank\">White Paper</a>, Corcept Therapeutics (<a href='https://seekingalpha.com/symbol/CORT' title='Corcept Therapeutics Incorporated'>CORT</a> <font color=\"green\">+3.2%</font>) refutes each allegation from short-sellers regarding Cushing's syndrome med KORLYM (mifepristone). Highlights:</li><li>Its says the current number of U.S. patients, at least 10K, is more than enough to account for revenue.</li><li>Prescription clusters in rural and suburban areas reflect doctors who are \"diligently diagnosing and treating patients\" and have nothing to do with improper payments. No doctors are paid for prescribing KORLYM.</li><li>99% of prescriptions are consistent with labeling. Off-label promotion is fiction.</li><li>Shares had sold off almost <font color=\"red\">40%</font> after Southern Investigative Reporting Foundation &#40;SIRF&#41; released a <a href=\"https://seekingalpha.com/news/3426124-corcept-6-percent-bearish-report\" target=\"_blank\">bearish report</a> in late January.</li><li>Blue Orca Capital apparently has not read the White Paper. It just released its own <a href=\"https://static1.squarespace.com/static/5a81b554be42d6b09e19fc09/t/5c59972053450a0642803d63/1549375265703/Blue+Orca+Short+Corcept+Therapeutics+%28NASDAQ+CORT%29.pdf\" target=\"_blank\">bearish take</a> on the company and sees almost 50% downside risk.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429652\" data-linked=\"Corcept issues rebuttal to short-sellers\" data-tweet=\"$CORT - Corcept issues rebuttal to short-sellers https://seekingalpha.com/news/3429652-corcept-issues-rebuttal-to-short-sellers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429652-corcept-issues-rebuttal-to-short-sellers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429648\" data-ts=\"1549385045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429648-israeli-telecoms-rise-after-allots-strong-q4-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Israeli telecoms rise after Allot&#39;s strong Q4 revenues</a></h4><ul>   <li>Israeli telecoms are higher in U.S. trading, in the wake of a <a href=\"https://seekingalpha.com/news/3429602-allot-plus-9_6-percent-revenue-growth-proceeds-double-digits\" target=\"_blank\">solid revenue performance</a> from Allot Communications (<a href=\"http://seekingalpha.com/symbol/ALLT\" target=\"_blank\">ALLT</a> <font color=\"green\">+5.6%</font>).</li>    <li>Cellcom Israel (NYSE:<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel, Ltd.'>CEL</a>) is <font color=\"green\">up 2.8%</font> and Partner Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/PTNR' title='Partner Communications Company Ltd.'>PTNR</a>) is <font color=\"green\">up 1.7%</font>.</li>    <li>In Tel Aviv, Bezeq (<a href='https://seekingalpha.com/symbol/BZQIY' title='Bezeq The Israel Telecommunication Corp Ltd. ADR'>OTCPK:BZQIY</a>) closed <font color=\"green\">up 2.7%</font>. On Nasdaq, Bezeq parent B Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/BCOM' title='B Communications Ltd.'>BCOM</a>) is <font color=\"green\">up 9.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429648\" data-linked=\"Israeli telecoms rise after Allot&#39;s strong Q4 revenues\" data-tweet=\"$CEL $CEL $PTNR - Israeli telecoms rise after Allot&#39;s strong Q4 revenues https://seekingalpha.com/news/3429648-israeli-telecoms-rise-after-allots-strong-q4-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3429648-israeli-telecoms-rise-after-allots-strong-q4-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429642\" data-ts=\"1549384903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROLL\" target=\"_blank\">ROLL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429642-rbc-bearings-down-6-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC Bearings down ~6% post Q3 results</a></h4><ul><li>RBC Bearings (<a href='https://seekingalpha.com/symbol/ROLL' title='RBC Bearings Incorporated'>ROLL</a> <font color=\"red\">-6.9%</font>) reported Q3 net sales growth of 2.8% Y/Y to $171.5M; and organic sales growth of 6.5% Y/Y.</li><li>Sales by segments: Plain bearings $79.31M (+13.7% Y/Y); Roller bearings $34.84M (+7.3% Y/Y); Ball bearings $16.72M (+1.4% Y/Y); and Engineered products $40.59M (-15.6% Y/Y).</li><li>Q3 Gross margin <font color=\"green\">improved by 90 bps</font> to 39.7%; operating margin <font color=\"red\">declined by 830 bps</font> to 11.6%; and adj. operating income <font color=\"green\">improved by 80 bps</font> to 21.4%.</li><li>SG&amp;A expenses increased by 3.5% Y/Y to $29.14M and margin was 17% <font color=\"red\">up by 12 bps</font>.</li><li>Backlog was at $428.2M (+9.2% Y/Y), as of December 29, 2018.</li><li>Cash provided by operating activities in the quarter was $21.15M, compared to $28.53M a year ago.</li><li><strong>4Q19 Outlook:</strong> Net sales to be ~$178M to $180M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429519-rbc-bearings-eps-line-misses-revenue\" target=\"_blank\">RBC Bearings EPS in-line, misses on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429642\" data-linked=\"RBC Bearings down ~6% post Q3 results\" data-tweet=\"$ROLL - RBC Bearings down ~6% post Q3 results https://seekingalpha.com/news/3429642-rbc-bearings-down-6-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3429642-rbc-bearings-down-6-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429645\" data-ts=\"1549384876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBIX\" target=\"_blank\">EBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429645-third-party-firm-says-ebix-remediated-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Third-party firm says Ebix remediated weakness</a></h4><ul><li>Ebix (NASDAQ:<a href='https://seekingalpha.com/symbol/EBIX' title='Ebix Inc'>EBIX</a>) <a href=\"https://seekingalpha.com/pr/17401495-renowned-north-american-firm-specializes-accounting-investigations-compliance-concludes-ebix\" target=\"_blank\">reports </a>that a \"renowned\" third-party accounting investigation firm has concluded that EBIX has remediated the weakness in its internal controls that were declared during the Q4 2017 report.</li><li>The company's audit committee accepts the firm's results, but the final decision on remediation will be made by Ebix's consolidated auditors, who are finishing the 2018 audit.</li><li>EBIX shares are <font color=\"green\">up 1.1%</font> to $58.68.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429645\" data-linked=\"Third-party firm says Ebix remediated weakness\" data-tweet=\"$EBIX - Third-party firm says Ebix remediated weakness https://seekingalpha.com/news/3429645-third-party-firm-says-ebix-remediated-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3429645-third-party-firm-says-ebix-remediated-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429640\" data-ts=\"1549384241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSDDF\" target=\"_blank\">FSDDF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429640-fsd-pharma-teams-up-solarvest-to-develop-cannabinoids\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FSD Pharma teams up with Solarvest to develop cannabinoids</a></h4><ul><li>FSD Pharma (<a href='https://seekingalpha.com/symbol/FSDDF' title='FSD Pharma Inc.'>OTCQB:FSDDF</a> <font color=\"green\">+1.1%</font>) <a href=\"https://seekingalpha.com/pr/17401210-fsd-pharma-announces-signing-loi-solarvest-develop-test-pharma-grade-cannabinoids-algae\" target=\"_blank\">inks </a>a non-binding letter of intent with Solarvest BioEnergy aimed a formal agreement to develop pharmaceutical-grade cannabinoids based on Solarvest's algal expression technology.</li><li>Solarvest will conduct the research while FSD will have exclusive rights to a subset of the cannabinoids and certain royalty rights to the rest.</li><li>Financial details are bit light, but Solarvest will pay a 5% royalty fee to FSD on Solarvest's sale or licensing of any the cannabinoids not licensed by FSD. Once Solarvest has paid FSD $3M, the rate will drop to 3%.</li><li>FSD will issue 10M common shares to Solarvest at $0.30 per share while Solarvest will issue 3M units to FSD at $0.20 per unit, each comprised of one common share and one two-year warrant to purchase one common share at $0.25. Solarvest will also issue a five-year $2.4M convertible note to FSD that will bear interest of 3% per annum and be convertible into Solarvest common stock at $1 per share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429640\" data-linked=\"FSD Pharma teams up with Solarvest to develop cannabinoids\" data-tweet=\"$FSDDF - FSD Pharma teams up with Solarvest to develop cannabinoids https://seekingalpha.com/news/3429640-fsd-pharma-teams-up-solarvest-to-develop-cannabinoids?source=tweet\" data-url=\"https://seekingalpha.com/news/3429640-fsd-pharma-teams-up-solarvest-to-develop-cannabinoids\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429637\" data-ts=\"1549383941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRL\" target=\"_blank\">CTRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429637-needham-downgrades-control4-on-headwinds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham downgrades Control4 on headwinds</a></h4><ul><li>Needham downgrades Control4 (NASDAQ:<a href='https://seekingalpha.com/symbol/CTRL' title='Control4 Corporation'>CTRL</a>) from Buy to Hold after earnings.</li><li>The firm notes that CTRL's top-line guidance assumes a soft Q1 with a reacceleration in the second half as a number of initiatives take hold. But Needham thinks headwinds from the weak macro environment could make the embedded reacceleration challenging.</li><li>Control4 shares are <font color=\"red\">down 17.1%</font> to $17.61.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429329-control4-minus-8-percent-mixed-q4-downside-guide\" target=\"_blank\">Control4 -8% on mixed Q4, downside guide</a> (Feb. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429637\" data-linked=\"Needham downgrades Control4 on headwinds\" data-tweet=\"$CTRL - Needham downgrades Control4 on headwinds https://seekingalpha.com/news/3429637-needham-downgrades-control4-on-headwinds?source=tweet\" data-url=\"https://seekingalpha.com/news/3429637-needham-downgrades-control4-on-headwinds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429634\" data-ts=\"1549383163\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBPMF\" target=\"_blank\">TBPMF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429634-tetra-bio-down-20-on-suspension-of-late-stage-study-of-ppp001\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tetra Bio down 20% on suspension of late-stage study of PPP001</a></h4><ul><li>Thinly traded micro cap Tetra Bio-Pharma (<a href='https://seekingalpha.com/symbol/TBPMF' title='Tetra Bio-Pharma Inc.'>OTCQB:TBPMF</a> <font color=\"red\">-19.6%</font>) slumps on a 7x surge in volume, albeit on turnover of only 418K shares, following the <a href=\"https://clinicaltrials.gov/ct2/show/NCT03339622?spons=tetra&amp;phase=2&amp;rank=1\" target=\"_blank\">suspension </a>of its <a href=\"https://clinicaltrials.gov/ct2/show/NCT03339622?spons=tetra&amp;phase=2&amp;rank=1\" target=\"_blank\">Phase 3 clinical trial</a> evaluating cannabis-derived PPP001 for pain management in cancer patients. The company took action after impurities were found in the drug.</li><li>Management says the situation will delay the filing of its Canadian marketing application by six months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429634\" data-linked=\"Tetra Bio down 20% on suspension of late-stage study of PPP001\" data-tweet=\"$TBPMF - Tetra Bio down 20% on suspension of late-stage study of PPP001 https://seekingalpha.com/news/3429634-tetra-bio-down-20-on-suspension-of-late-stage-study-of-ppp001?source=tweet\" data-url=\"https://seekingalpha.com/news/3429634-tetra-bio-down-20-on-suspension-of-late-stage-study-of-ppp001\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429628\" data-ts=\"1549382678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRVN\" target=\"_blank\">TRVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429628-trevena-leads-healthcare-gainers-opko-health-and-pain-therapeutics-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trevena leads healthcare gainers; OPKO Health and Pain Therapeutics among losers</a></h4><ul><li><b>Gainers: </b>Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) <font color=\"green\">+15%</font>. Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a>) <font color=\"green\">+15%</font>. INSYS Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a>) <font color=\"green\">+13%</font>. China SXT Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SXTC' title='China SXT Pharmaceuticals, Inc.'>SXTC</a>) <font color=\"green\">+11%</font>. EDAP TMS (NASDAQ:<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>OPKO Health (NYSEMKT:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) <font color=\"red\">-19%</font>. Luminex (NASDAQ:<a href='https://seekingalpha.com/symbol/LMNX' title='Luminex Corporation'>LMNX</a>) <font color=\"red\">-14%</font>. Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>) <font color=\"red\">-12%</font>. Cellect Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a>) <font color=\"red\">-11%</font>. Trillium Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIL' title='Trillium Therapeutics Inc.'>TRIL</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429628\" data-linked=\"Trevena leads healthcare gainers; OPKO Health and Pain Therapeutics among losers\" data-tweet=\"$TRVN $TRVN $ALRN - Trevena leads healthcare gainers; OPKO Health and Pain Therapeutics among losers https://seekingalpha.com/news/3429628-trevena-leads-healthcare-gainers-opko-health-and-pain-therapeutics-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429628-trevena-leads-healthcare-gainers-opko-health-and-pain-therapeutics-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429626\" data-ts=\"1549382631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTHF\" target=\"_blank\">VRTHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429626-veritas-to-reverse-split-shares-1-10-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veritas to reverse split shares 1:10; shares down 4%</a></h4><ul><li>Veritas Pharma (<a href='https://seekingalpha.com/symbol/VRTHF' title='Veritas Pharma Inc'>OTCPK:VRTHF</a> <font color=\"red\">-3.7%</font>) will <a href=\"https://seekingalpha.com/pr/17401150-veritas-pharma-proceed-share-consolidation\" target=\"_blank\">execute </a>a 1:10 reverse split of its common stock effective after the close on Friday, February 8. Post-split trading on the Canadian Securities Exchange will commence on Monday, February 11.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429626\" data-linked=\"Veritas to reverse split shares 1:10; shares down 4%\" data-tweet=\"$VRTHF - Veritas to reverse split shares 1:10; shares down 4% https://seekingalpha.com/news/3429626-veritas-to-reverse-split-shares-1-10-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3429626-veritas-to-reverse-split-shares-1-10-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429627\" data-ts=\"1549382629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNX\" target=\"_blank\">CNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429627-cnx-resourcesplus-4-utica-gas-well-remediated-contained\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNX Resources +4% as Utica gas well remediated, contained</a></h4><ul><li>CNX Resources (<a href='https://seekingalpha.com/symbol/CNX' title='CNX Resources Corporation'>CNX</a> <font color='green'>+4.1%</font>) shoots higher after announcing a <a href=\"https://seekingalpha.com/pr/17401353-cnx-provides-information-successful-remediation-shaw-1g-utica-well\" target=\"_blank\">successful remediation</a> process to arrest the <a href=\"https://seekingalpha.com/news/3429003-cnx-resources-stops-utica-well-gas-release\" target=\"_blank\">subsurface flow of gas</a> at the Shaw 1G well in Pennsylvania's Utica shale.</li><li>CNX believes the pressure anomaly experienced during hydraulic fracturing operations is isolated to the Shaw 1G well.</li><li>CNX says all frac operations on  the 4-well Shaw pad remain suspended while the incident continues to be assessed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429627\" data-linked=\"CNX Resources +4% as Utica gas well remediated, contained\" data-tweet=\"$CNX - CNX Resources +4% as Utica gas well remediated, contained https://seekingalpha.com/news/3429627-cnx-resourcesplus-4-utica-gas-well-remediated-contained?source=tweet\" data-url=\"https://seekingalpha.com/news/3429627-cnx-resourcesplus-4-utica-gas-well-remediated-contained\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429623\" data-ts=\"1549381963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQST\" target=\"_blank\">AQST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429623-indivior-fails-in-appeal-to-reinstate-injunction-against-generic-competitor-to-suboxone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Indivior fails in appeal to reinstate injunction against generic competitor to Suboxone; shares down 5%</a></h4><ul><li>The U.S. Court of Appeals for the Federal Circuit has <a href=\"https://seekingalpha.com/pr/17401560-aquestive-therapeutics-provides-update-regarding-suboxone-sublingual-film-litigation\" target=\"_blank\">denied </a>a motion from Indivior (<a href='https://seekingalpha.com/symbol/INVVY' title='INDIVIOR PLC ADR'>OTCPK:INVVY</a> <font color=\"red\">-5.2%</font>) for a rehearing to reinstate the preliminary injunction against Dr. Reddy's Laboratories (<a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a> <font color=\"green\">+0.7%</font>) stopping it from marketing a generic version of opioid dependence treatment <a href=\"https://www.suboxone.com/\" target=\"_blank\">Suboxone</a> (buprenorphine/naloxone) Sublingual Film.</li><li>The ruling is not a judgement in the ongoing patent infringement litigation.</li><li>Aquestive Therapeutics (<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics'>AQST</a> <font color=\"green\">+5.1%</font>) is the sole and exclusive manufacturer of the brand and authorized generic versions and expects to continue making and delivering a \"significant volume\" of Suboxone this year to licensee Indivior.</li><li><strong>Update</strong>: On February 20, RDY <a href=\"https://seekingalpha.com/pr/17418487-dr-reddys-laboratories-announces-re-launch-buprenorphine-naloxone-sublingual-film-favorable\" target=\"_blank\">announced </a>the relaunch of its product.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429623\" data-linked=\"Indivior fails in appeal to reinstate injunction against generic competitor to Suboxone; shares down 5%\" data-tweet=\"$AQST $RDY $INVVY - Indivior fails in appeal to reinstate injunction against generic competitor to Suboxone; shares down 5% https://seekingalpha.com/news/3429623-indivior-fails-in-appeal-to-reinstate-injunction-against-generic-competitor-to-suboxone?source=tweet\" data-url=\"https://seekingalpha.com/news/3429623-indivior-fails-in-appeal-to-reinstate-injunction-against-generic-competitor-to-suboxone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429614\" data-ts=\"1549380890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONO\" target=\"_blank\">SONO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429614-sonos-launches-outdoor-speaker\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sonos launches outdoor speaker</a></h4><ul><li>Sonos (NASDAQ:<a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a>) <a href=\"https://seekingalpha.com/pr/17402143-sonos-unveils-sonos-architectural-sonance-first-premium-architectural-speakers-designed-use\" target=\"_blank\">launches </a>an outdoor speaker with the Sonos Architectural by Sonance collection.</li><li>The collection is meant to work with the Sonos Amp for whole-home streaming.</li><li>Sonos Outdoor has a weatherproof design that can withstand the elements year-round.</li><li>Sonos In-Wall and Sonos In-Ceiling are indoor speakers with paintable grilles to help the devices match the living space.</li><li>Sonos says one Amp can power up to three pairs of Architectural by Sonance speakers.</li><li>Price and availability: The In-Wall and In-Ceiling speakers cost $599 a pair with preorders available now with shipments starting February 26. The $799 per pair Outdoor will launch in April. The $599 Amp, previously limited to the United States, will start expanding its markets today to include Australia, Canada, Mexico, and Europe.</li><li>Sonos shares are <font color=\"green\">up 4%</font> to $13.58.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429614\" data-linked=\"Sonos launches outdoor speaker\" data-tweet=\"$SONO - Sonos launches outdoor speaker https://seekingalpha.com/news/3429614-sonos-launches-outdoor-speaker?source=tweet\" data-url=\"https://seekingalpha.com/news/3429614-sonos-launches-outdoor-speaker\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429613\" data-ts=\"1549380813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVCO\" target=\"_blank\">CVCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429613-cavco-industries-down-11-post-q3-results-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cavco Industries down 11% post Q3 results miss</a></h4><ul><li>Cavco Industries (<a href='https://seekingalpha.com/symbol/CVCO' title='Cavco Industries, Inc.'>CVCO</a> <font color=\"red\">-11.6%</font>) Q3 revenue increased by 5.6% Y/Y to $233.7M, primarily from higher home selling prices as a result of input cost inflation and modestly larger home sizes.</li><li>Revenue by segment: Factory-built housing $220.34M (+6.3% Y/Y); and Financial services $13.36M (-5.9% Y/Y).</li><li>Q3 Gross margin <font color=\"red\">declined by 155 bps</font> to 20.9%; and operating income <font color=\"red\">declined by 297 bps </font>to 7.8%.</li><li>Total factory-built homes sold were 3,447 a decrease of 6.8% Y/Y.</li><li>SG&amp;A expenses were $30.83M (+18.4% Y/Y) and margin was 13.2% <font color=\"red\">up by 143 bps</font>.</li><li>Backlog of orders was at $166M at the end the quarter, lower than last year by $41M.</li><li>Current quarter results were impacted by unrealized losses of $2.1M on corporate equity investments; Expenses of $1.3M for legal and other expenses related to the Company's internal investigation; and severe hailstorm in Arizona, which resulted in increased homeowners' insurance claims.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429272-cavco-misses-0_05-misses-revenue\" target=\"_blank\">Cavco misses by $0.05, misses on revenue</a> (Feb. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429613\" data-linked=\"Cavco Industries down 11% post Q3 results miss\" data-tweet=\"$CVCO - Cavco Industries down 11% post Q3 results miss https://seekingalpha.com/news/3429613-cavco-industries-down-11-post-q3-results-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3429613-cavco-industries-down-11-post-q3-results-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429612\" data-ts=\"1549380624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIA\" target=\"_blank\">ACIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429612-acacia-well-positioned-for-600g-customers-cowen-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acacia well positioned for 600G with customers, Cowen says</a></h4><ul>   <li>Acacia Communications (<a href=\"http://seekingalpha.com/symbol/ACIA\" target=\"_blank\">ACIA</a> <font color=\"green\">+2.7%</font>) is well set up for 600G, Cowen says, and shares are higher today.</li>    <li>The company's the only viable commercial merchant supplier of 600G and 1.2T per wavelength coherent DSPs/modules, analyst Paul Silverstein writes, and that means traction with customers: Checks indicate a strong early ramp in deployment of its 1.2T AC-1200 module by the likes of Microsoft and Google, and the company's likely to take advantage of a significant upgrade opportunity at Facebook worth up to $10M-$20M in incremental revenue in the coming two years. (h/t Bloomberg)</li>    <li>He has an Outperform rating and a $45 price target, though the target now implies just 3.5% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429612\" data-linked=\"Acacia well positioned for 600G with customers, Cowen says\" data-tweet=\"$ACIA - Acacia well positioned for 600G with customers, Cowen says https://seekingalpha.com/news/3429612-acacia-well-positioned-for-600g-customers-cowen-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3429612-acacia-well-positioned-for-600g-customers-cowen-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429609\" data-ts=\"1549380260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLMT\" target=\"_blank\">CLMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429609-calumet-specialtyplus-8-self-help-phase-1-realizes-180m-in-ebitda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calumet Specialty +8% as Self-Help Phase 1 realizes $180M in EBITDA</a></h4><ul><li>Calumet Specialty Products (<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+7.6%</font>) is higher after saying it has <a href=\"https://seekingalpha.com/pr/17401101-calumet-specialty-products-partners-l-p-announces-completion-phase-outlines-phase-ii-companys\" target=\"_blank\">realized more than $180M in EBITDA</a> from Phase 1 of its  Self-Help program at year-end 2018 and anticipates capturing an incremental $100M in EBITDA during 2019-21 from its Phase 2 Self-Help program.</li><li>CLMT says two-thirds of Phase II is focused on improving its core Specialty business and expects to spend $25M-$40M to achieve these results over the new three-year period.</li><li>CLMT also says it will continue to have sufficient liquidity to meet its financial commitments, debt service obligations, contingencies and anticipated capital spending.</li><li>However, given the Q4 drop in crude oil prices, the company says it expects to report a negative non-cash lower of cost or market adjustment to its inventories when it reports Q4 results, hurting net income and adjusted EBITDA levels.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429609\" data-linked=\"Calumet Specialty +8% as Self-Help Phase 1 realizes $180M in EBITDA\" data-tweet=\"$CLMT - Calumet Specialty +8% as Self-Help Phase 1 realizes $180M in EBITDA https://seekingalpha.com/news/3429609-calumet-specialtyplus-8-self-help-phase-1-realizes-180m-in-ebitda?source=tweet\" data-url=\"https://seekingalpha.com/news/3429609-calumet-specialtyplus-8-self-help-phase-1-realizes-180m-in-ebitda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429605\" data-ts=\"1549379683\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EL\" target=\"_blank\">EL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429605-baml-positive-on-estee-lauder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML positive on Estee Lauder</a></h4><ul> <li>Bank of America Merrill Lynch says Estee Lauder (NYSE:<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a>) likely quelled investor concerns about a slowdown with its \"robust\" FQ2 report and guidance update.</li> <li>The firm keeps a Buy rating on Estee Lauder and price objective of $155 (30X the FY19 EPS estimate). \"We believe the premium is well justified by a sustainably higher growth rate and multiple business improvement opportunities,\" notes BAML on the price target.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3429479-estee-lauder-plus-10-percent-earnings-beat\" target=\"_blank\">Estee Lauder +10% on earnings beat</a> (Feb. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3429605\" data-linked=\"BAML positive on Estee Lauder\" data-tweet=\"$EL - BAML positive on Estee Lauder https://seekingalpha.com/news/3429605-baml-positive-on-estee-lauder?source=tweet\" data-url=\"https://seekingalpha.com/news/3429605-baml-positive-on-estee-lauder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429602\" data-ts=\"1549379530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALLT\" target=\"_blank\">ALLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429602-allotplus-9_6-revenue-growth-proceeds-double-digits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allot +9.6% as revenue growth proceeds by double digits</a></h4><ul>   <li>Allot Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLT' title='Allot Communications Ltd.'>ALLT</a>) is <font color=\"green\">up 9.6%</font> after it beat expectations on top and bottom lines in its Q4 earnings, and guided to strong revenue growth for the coming year.</li>    <li>Revenues were up 16% and the company narrowed its non-GAAP operating loss to $99,000 from a year-ago loss of $1.3M.</li>    <li>Gross profit rose 19% to $18.9M; Net loss improved to $455,000 from a year-ago loss of $1.5M.</li>    <li>\"Our DPI business performed well in 2018, resulting from much improved execution of our teams across the globe,\" says CEO Erez Antebi. \"We are also satisfied with our performance in the security space: our pipeline of 'security opex deals' is strong and we expect to close several such deals that can bring impact on our future growth beyond 2019.\"</li>    <li>It's guiding to 2019 revenues of $106M-$110M -- above consensus expectations for $103.7M -- with book-to-bill ratio above 1.</li>    <li>It also says it expecting to close several security subscription-based deals this year, in addition to a recently announced Tier 1 European deal.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429391-allot-communications-beats-0_02-beats-revenue\" target=\"_blank\">Allot Communications beats by $0.02, beats on revenue</a> (Feb. 05 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17401254-allot-announces-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3429602\" data-linked=\"Allot +9.6% as revenue growth proceeds by double digits\" data-tweet=\"$ALLT - Allot +9.6% as revenue growth proceeds by double digits https://seekingalpha.com/news/3429602-allotplus-9_6-revenue-growth-proceeds-double-digits?source=tweet\" data-url=\"https://seekingalpha.com/news/3429602-allotplus-9_6-revenue-growth-proceeds-double-digits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429601\" data-ts=\"1549379483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IT\" target=\"_blank\">IT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429601-gartnerminus-4_8-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gartner -4.8% post Q4 results</a></h4><ul><li>Gartner (<a href='https://seekingalpha.com/symbol/IT' title='Gartner Inc.'>IT</a> <font color=\"red\">-4.8%</font>) <a href=\"https://seekingalpha.com/pr/17401294-gartner-reports-fourth-quarter-2018-financial-results\" target=\"_blank\">Q4</a> revenue rose 6.9% Y/Y to $1.09B, if the impact of the foreign exchange is backed out.</li><li>Segment revenue: Research: $796M (+9.5%); Consulting: $96M (+12.9%); Conferences: $196M (+16%).</li><li>Global Technology Sales Contract Value was up 14% to $2.6B &amp; Global Business Sales Contract Value up 1% to $0.6B.</li><li>Operating cash flow was $45M &amp; free cash flow of $7M.</li><li>The Company repurchased 1.1M common shares for $156M.</li><li>Also, paid down $1B of debt during the year.</li><li><b>FY2019 Guidance</b>: Total revenue: $4.22-4.32B; Net income $238-272M; GAAP EPS: $2.65-3.03; Adjusted EPS of $3.82-4.19; Adjusted EBITDA $750-765M; Operating cash flow: $542-582M &amp; FCF $455-485M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429408-gartner-misses-0_05-misses-revenue\" target=\"_blank\">Gartner misses by $0.05, misses on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429601\" data-linked=\"Gartner -4.8% post Q4 results\" data-tweet=\"$IT - Gartner -4.8% post Q4 results https://seekingalpha.com/news/3429601-gartnerminus-4_8-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3429601-gartnerminus-4_8-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429598\" data-ts=\"1549379129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDG\" target=\"_blank\">TDG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429598-transdigmplus-5-after-easy-q1-beat-upsized-full-year-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransDigm +5% after easy Q1 beat, upsized full-year guidance</a></h4><ul><li>TransDigm (<a href='https://seekingalpha.com/symbol/TDG' title='TransDigm Group Incorporated'>TDG</a> <font color=\"green\">+4.8%</font>) jumps to a 52-week high after trouncing <a href=\"https://seekingalpha.com/news/3429480-transdigm-group-beats-0_42-beats-revenue\" target=\"_blank\">FQ1 earnings</a> and revenue estimates and raising guidance for full-year earnings, revenue and EBITDA.</li><li>Net sales for the quarter rose 17% Y/Y to $993.3M, the company's fourth straight quarter of accelerating revenue growth, from $848M a year ago; organic sales growth was 11.6%.</li><li>TDG says its Q4 EBITDA As Defined margin of 49% increased more than 150 bps in spite of margin dilution from acquisitions completed in FY 2018.</li><li>For FY 2019, TDG raises guidance for EPS to $16.42-$17.10 from $15.92-$16.60 previously and in line with $16.60 analyst consensus estimate, and for revenues of $4.145B-$4.235B from  $4.125B-$4.215B previously and in line with $4.17B consensus.</li><li>TDG also lifts its full-year forecast for EBITDA As Defined to $2.065B-$2.115B million from $2.045B-$2.095B, compared with $1.877B in FY 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429598\" data-linked=\"TransDigm +5% after easy Q1 beat, upsized full-year guidance\" data-tweet=\"$TDG - TransDigm +5% after easy Q1 beat, upsized full-year guidance https://seekingalpha.com/news/3429598-transdigmplus-5-after-easy-q1-beat-upsized-full-year-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3429598-transdigmplus-5-after-easy-q1-beat-upsized-full-year-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429579\" data-ts=\"1549377676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429579-mallinckrodts-acthar-gel-shows-treatment-effect-in-post-market-rheumatoid-arthritis-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt&#39;s Acthar Gel shows treatment effect in post-market rheumatoid arthritis study; shares up 2%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17401375-mallinckrodt-provides-update-phase-4-data-h-p-acthar-gel-repository-corticotropin-injection\" target=\"_blank\">Results </a>from the open-label stage of a Phase 4 clinical trial evaluating Mallinckrodt's (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color=\"green\">+1.8%</font>) H.P. Acthar Gel in patients with persistently active rheumatoid arthritis &#40;RA&#41; who previously received disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids showed a treatment effect consistent with earlier assessments.</li><li>Specifically, 61% (n=61/100) of treated patients who completed the open-label period achieved low disease activity at week 12.</li><li>Complete data from the open-label phase should be available mid-year.</li><li>The company says that the results cannot be solely attributed to H.P. Acthar Gel since patients were on different medications at the start of the trial and no washout periods were undertaken, adding that the product has not been formally studied in combination with other treatments.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429579\" data-linked=\"Mallinckrodt&#39;s Acthar Gel shows treatment effect in post-market rheumatoid arthritis study; shares up 2%\" data-tweet=\"$MNK - Mallinckrodt&#39;s Acthar Gel shows treatment effect in post-market rheumatoid arthritis study; shares up 2% https://seekingalpha.com/news/3429579-mallinckrodts-acthar-gel-shows-treatment-effect-in-post-market-rheumatoid-arthritis-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3429579-mallinckrodts-acthar-gel-shows-treatment-effect-in-post-market-rheumatoid-arthritis-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429571\" data-ts=\"1549376955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTIE\" target=\"_blank\">PTIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429571-pain-therapeutics-down-23-premarket-on-lack-of-progress-remoxy-nda-refiling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pain Therapeutics down 23% premarket on lack of progress with Remoxy NDA refiling</a></h4><ul><li>Thinly traded nano cap Pain Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a>) slumps <font color=\"red\">23%</font> premarket on increased volume in reaction to the <a href=\"https://seekingalpha.com/pr/17401626-pain-therapeutics-announces-feedback-recent-meeting-fda-remoxy\" target=\"_blank\">results </a>from its meeting with the FDA aimed at getting its REMOXY ER (oxycodone extended-release CII) marketing application back on track. The company received a second CRL in August 2018 citing the need for still more data demonstrating that the benefits outweigh the risks.</li><li>The company believes it is no closer to approval than it was a year ago. During the meeting, the agency apparently maintained its position that it made no math errors, material mistakes or misrepresentations during the advisory committee meeting last June.</li><li>The main issue appears to be the FDA concern that REMOXY ER lacks abuse deterrence via the injection route because oxycodone can be extracted from the product.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3366404-joint-fda-panel-votes-pain-therapeutics-remoxy-er\" target=\"_blank\">Joint FDA panel votes against Pain Therapeutics' Remoxy ER</a> (June 26, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429571\" data-linked=\"Pain Therapeutics down 23% premarket on lack of progress with Remoxy NDA refiling\" data-tweet=\"$PTIE $SAVA - Pain Therapeutics down 23% premarket on lack of progress with Remoxy NDA refiling https://seekingalpha.com/news/3429571-pain-therapeutics-down-23-premarket-on-lack-of-progress-remoxy-nda-refiling?source=tweet\" data-url=\"https://seekingalpha.com/news/3429571-pain-therapeutics-down-23-premarket-on-lack-of-progress-remoxy-nda-refiling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429570\" data-ts=\"1549376941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPI\" target=\"_blank\">GPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429570-on-group-1-automotives-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Group 1 Automotive&#39;s Q4 beat</a></h4><ul><li>Group 1 Automotive (NYSE:<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a>) reports total revenue rose 0.8% on a constant currency basis in <a href=\"https://seekingalpha.com/pr/17401442-group-1-automotive-reports-fourth-quarter-and-full-year-2018-financial-results\" target=\"_blank\">Q4</a>.</li><li>Total same-store sales dropped 3% to $2.79B.</li><li>Same-store sales decreased 1.3% for U.S., 8% for U.K. and 12.5% for Brazil.</li><li>Revenue break-up: New vehicle retail sales: $1.57B (-5.3%); Used vehicle retail sales: $771.24M (+8.8%); Used vehicle wholesale sales: $86.12M (-6.2%); Parts and service: $354.74M (+3.3%); Finance and insurance: $123.99M (+8.1%).</li><li>Geographic sales break-up: U.S.: $2.27B (-0.9%); U.K.: $524.02M (+3.2%); Brazil: $118.25M (-5.7%).</li><li>Gross margin rate grew 30 bps to 14.9%.</li><li>Adjusted SG&amp;A expense rate +50 bps to 11.1%.</li><li>Adjusted operating margin rate down 30 bps to 3.2%.</li><li>Total units sold +5.7% Y/Y to 48,188 units.</li><li>During Q4, the Company repurchased 1,313,786 shares at an average price of $57.31 per share for a total of $75.3M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429467-group-1-automotive-beats-0_03-beats-revenue\" target=\"_blank\">Group 1 Automotive beats by $0.03, beats on revenue</a> (Feb. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3429570\" data-linked=\"More on Group 1 Automotive&#39;s Q4 beat\" data-tweet=\"$GPI - More on Group 1 Automotive&#39;s Q4 beat https://seekingalpha.com/news/3429570-on-group-1-automotives-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3429570-on-group-1-automotives-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429569\" data-ts=\"1549376916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429569-moleculin-biotechplus-10-on-receiving-orphan-drug-status-for-brain-tumor-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin Biotech +10% on receiving Orphan Drug status for brain tumor drug</a></h4><ul> <li>The FDA has <a href=\"https://seekingalpha.com/pr/17401462-moleculin-announces-fda-granted-orphan-drug-designation-brain-tumor-drug\" target=\"_blank\">granted</a> Orphan Drug status to Moleculin Biotech's (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li><li>Shares are up <font color=\"green\">10%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3429569\" data-linked=\"Moleculin Biotech +10% on receiving Orphan Drug status for brain tumor drug\" data-tweet=\"$MBRX - Moleculin Biotech +10% on receiving Orphan Drug status for brain tumor drug https://seekingalpha.com/news/3429569-moleculin-biotechplus-10-on-receiving-orphan-drug-status-for-brain-tumor-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3429569-moleculin-biotechplus-10-on-receiving-orphan-drug-status-for-brain-tumor-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429564\" data-ts=\"1549376547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPK\" target=\"_blank\">OPK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429564-opko-health-prices-convertible-debt-offering-shares-down-18-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OPKO Health prices convertible debt offering; shares down 18% premarket</a></h4><ul> <li>OPKO Health (NYSEMKT:<a href='https://seekingalpha.com/symbol/OPK' title='OPKO Health, Inc.'>OPK</a>) <a href=\"https://seekingalpha.com/pr/17401796-opko-health-inc-announces-pricing-offering-convertible-senior-notes\" target=\"_blank\">prices</a> its $200M aggregate principal amount of 4.50% Convertible Senior Notes due 2025.</li><li>The initial conversion rate will be 236.7424 shares of common stock per $1,000 (~$4.22/share).</li><li>Underwriters over-allotment is an additional $30M Notes.</li><li>Net proceeds will be used for commercialization of pharmaceutical and diagnostic products and for working capital and other general corporate purposes, including repayment or repurchase of indebtedness or debt securities.</li>     <li>Closing date is February 7.</li><li>Shares are down <font color=\"red\">18%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3429316-opko-5-percent-hours-convertible-debt-offering\" target=\"_blank\">OPKO down 5% after hours on convertible debt offering</a> (Feb. 4)</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3429564\" data-linked=\"OPKO Health prices convertible debt offering; shares down 18% premarket\" data-tweet=\"$OPK - OPKO Health prices convertible debt offering; shares down 18% premarket https://seekingalpha.com/news/3429564-opko-health-prices-convertible-debt-offering-shares-down-18-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3429564-opko-health-prices-convertible-debt-offering-shares-down-18-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429560\" data-ts=\"1549376221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429560-rl-box-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RL, BOX among premarket gainers</a></h4><ul><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) <font color=\"green\">+41%</font> on $255M cannabinoid <a href=\"https://seekingalpha.com/news/3429543-amyris-41-percent-premarket-255m-cannabinoid-deal\" target=\"_blank\">deal</a>.</li><li>Melinta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNT' title='Melinta Therapeutics'>MLNT</a>) <font color=\"green\">+19% </font>on increased volume following yesterday's <a href=\"https://seekingalpha.com/news/3429056-melinta-therapeutics-provides-corporate-updates\" target=\"_blank\">corporate update</a>.</li><li>Moleculin Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a>) <font color=\"green\">+12%</font> as FDA has <a href=\"https://seekingalpha.com/pr/17401462-moleculin-announces-fda-granted-orphan-drug-designation-brain-tumor-drug\" target=\"_blank\">granted</a> Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.</li><li>Codexis (NASDAQ:<a href='https://seekingalpha.com/symbol/CDXS' title='Codexis, Inc.'>CDXS</a>) <font color=\"green\">+12%</font> on Merck <a href=\"https://seekingalpha.com/news/3429505-codexis-13-percent-premarket-merck-deal\" target=\"_blank\">deal</a>.</li><li>Allot (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLT' title='Allot Communications Ltd.'>ALLT</a>) <font color=\"green\">+10%</font> on Q4 <a href=\"https://seekingalpha.com/news/3429391\" target=\"_blank\">earnings</a>.</li><li>The Estee Lauder Companies (NYSE:<a href='https://seekingalpha.com/symbol/EL' title='Estee Lauder Companies, Inc. &#40;The&#41;'>EL</a>) <font color=\"green\">+10%</font> on Q2 <a href=\"https://seekingalpha.com/news/3429437-estee-lauder-beats-0_19-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Precision Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIPT' title='Precision Therapeutics Inc.'>AIPT</a>) <font color=\"green\">+9%</font> as its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the <a href=\"https://seekingalpha.com/pr/17401846-precision-therapeutics-tumorgenesis-division-isolates-discovery-biomarkers-thyroid-cancer\" target=\"_blank\">discovery biomarkers</a>.</li><li>QuickLogic (NASDAQ:<a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a>) <font color=\"green\">+7%</font>.</li><li>Ralph Lauren (NYSE:<a href='https://seekingalpha.com/symbol/RL' title='Ralph Lauren Corporation'>RL</a>) <font color=\"green\">+6%</font> on Q3 <a href=\"https://seekingalpha.com/news/3429520-ralph-lauren-beats-0_17-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) <font color=\"green\">+6%</font> on new Buy <a href=\"https://seekingalpha.com/news/3429516-box-plus-4_8-percent-new-buy-rating\" target=\"_blank\">rating</a>.</li><li>Centene (NYSE:<a href='https://seekingalpha.com/symbol/CNC' title='Centene Corporation'>CNC</a>) <font color=\"green\">+6%</font> on Q4 <a href=\"https://seekingalpha.com/news/3429410-centene-beats-0_06-beats-revenue\" target=\"_blank\">earnings</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3429560\" data-linked=\"RL, BOX among premarket gainers\" data-tweet=\"$AMRS $AMRS $MLNT - RL, BOX among premarket gainers https://seekingalpha.com/news/3429560-rl-box-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3429560-rl-box-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3429559\" data-ts=\"1549376043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKGAY\" target=\"_blank\">MKGAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3429559-merck-kgaa-teams-up-glaxo-to-develop-cancer-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck KGaA teams up with Glaxo to develop cancer candidate</a></h4><ul><li>Merck KGaA (<a href='https://seekingalpha.com/symbol/MKGAY' title='Merck KGaA ADR'>OTCPK:MKGAY</a>) inks a <a href=\"https://seekingalpha.com/pr/17401454-merck-kgaa-darmstadt-germany-gsk-announce-global-alliance-jointly-develop-commercialize-m7824\" target=\"_blank\">collaboration deal</a> with GlaxoSmithKline (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) to jointly develop and commercialize M7824, a bifunctional fusion protein, for treatment-resistant cancers.</li><li>Under the terms of the agreement, Glaxo will pay Merck \u20ac300M upfront and up to \u20ac2.9B in milestones. All profits and costs will be equally shared on a global basis. </li><li>M7824 (bintrafusp alfa) is a bifunctional immunotherapy designed to combine a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein, targeting two pathways that play key roles in cancer cell growth and proliferation. </li><li><p>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03631706?intr=M7824&amp;phase=1&amp;rank=2\" target=\"_blank\">Phase 2 trial</a> evaluating M7824 compared to U.S. Merck's (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) Keytruda (pembrolizumab) in first-line lung cancer is in process with an estimated primary completion date of October 2021. </p></li><li><p>GSK and MRK are up <font color=\"green\">1%</font> premarket, both on light volume. </p></li></ul><div class=\"tiny-share-widget\" data-id=\"3429559\" data-linked=\"Merck KGaA teams up with Glaxo to develop cancer candidate\" data-tweet=\"$MKGAY $GSK $MKGAY - Merck KGaA teams up with Glaxo to develop cancer candidate https://seekingalpha.com/news/3429559-merck-kgaa-teams-up-glaxo-to-develop-cancer-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3429559-merck-kgaa-teams-up-glaxo-to-develop-cancer-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}